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ABSTRACT
Current limitations regarding the treatment of metastatic epithelial ovarian cancer
(EOC) are attributed to our poor overall understanding of its progression due to the
limited number o f appropriate model systems. To this end, I have characterized EOC
tumour growth and angiogenesis using the innovative chick chorioallantoic membrane
(CAM) model system. Bone morphogenetic protein (BMP) signaling has been implicated
in multiple processes o f EOC metastasis, although its role in tumour angiogenesis has
never been assessed. I found an inverse correlation between the level o f BMP signaling in
mouse EOC cells and their abilities to induce angiogenesis both in vitro using HUVEC
tube formation assays and in vivo using a chick CAM angiogenesis collagen onplant
assay. These results support the further implementation o f the chick CAM as an
important tool to study EOC metastasis. Additionally, the putative anti-angiogenic role of
BMP4 signaling from my work highlights potential future implications for this pathway
in prognostics and treatment o f EOC.

Keywords: Bone Morphogenetic Protein, Chick Chorioallantoic Membrane, Epithelial
Ovarian Cancer, Angiogenesis, Tumour Formation, Metastasis
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CHAPTER ONE

INTRODUCTION

1.1

Overview of ovarian cancer

1.1.1

Prevalence and mortality
Ovarian cancer is the seventh most common type of cancer in women, and it is

estimated that there were 2,600 new cases o f ovarian cancer in Canada this past year.
This represents 3% of the 83,900 total new cases o f cancer among women in Canada in
2010 (Canada 2010). Although this is a fairly small percentage of the total number of
new cancer incidences, ovarian cancer is the most lethal gynecologic cancer in the
western world, and is responsible for more deaths than endometrial and cervical cancer
combined (Ozols, Bookman et al. 2004). This is highlighted by the fact that it was the
fifth deadliest cancer in terms of mortality in women, and accounted for approximately
5% of the 36,200 cancer related deaths among females in Canada in 2010 (Canada 2010).
Although much research has gone into developing treatments for ovarian cancer, there
was only a 0.5% decrease in mortality rates among women with ovarian cancer in Canada
between 1996 and 2005. Conversely, other cancers such as lung and breast cancer have
mortality rates that have decreased by over 2% during the same period of time.

1.1.2

Detection and screening for ovarian cancer
These recent successes in declining mortality rates for other cancers such as lung

and breast has been largely attributed to important advancements with respect to early
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detection and treatment (Canada 2010). Unfortunately, ovarian cancer is not usually
detected during its early stages due to a low specificity of recognizable signs and
symptoms (Goff, Mandel et al. 2007). The most common symptoms that women report
before they are diagnosed with ovarian cancer are pelvic and abdominal pain, bloating
and an increased size o f abdomen, increased frequency of urination, and a low desire to
eat for periods o f at least 1 year preceding diagnosis. Therefore, patients and physicians
will often attribute many of these symptoms to other general gynecological concerns such
as menstrual problems, aging, or menopause (Argento, Hoffman et al. 2008).
The most common methods that are currently used clinically to detect ovarian
cancer are transvaginal ultrasounds, and the measurement of blood circulating marker
CA-125 (Argento, Hoffman et al. 2008), which is an antigen that is expressed by the
coelomic epithelium (Jacobs and Menon 2004). However, there are several processes
other than ovarian cancer that can disrupt the coelomic epithelium such as pregnancy,
appendicitis, ovarian cysts, and endometriosis, thereby complicating the interpretations of
CA-125 blood test results (Cragun 2011). As well, CA-125 can be elevated in other
cancers such as pancreatic, uterine, and lung cancer. Overall, CA-125 is expressed in
approximately 50% o f early stage ovarian cancers. However, there is a large frequency of
false positives and false negatives in CA-125 screening, which suggests that this
screening method is not specific or sensitive enough to be used as a definitive tool to
diagnose ovarian cancer. The other common screening method that is used to detect
ovarian cancer is transvaginal ultrasounds, which attempt to differentiate benign from
malignant masses (Cragun 2011). Although this screening method is argued to be the
most effective current method for detecting early stage ovarian cancer, it is only able to
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distinguish between benign and malignant lesions between 68-81% of the time. Pelvic
exams can also be used in an attempt to distinguish between a normal ovary and one that
possesses early premalignant lesions, but studies show that these exams are only able to
distinguish between the two 45% o f the time.
With respect to assessing a woman’s risk of developing ovarian cancer, high-risk
populations with a family history of ovarian cancer may be screened for germline
mutations such as BRCA1 and BRCA2, as women with these mutations have a
dramatically increased risk of developing ovarian cancer (Antoniou, Pharoah et al. 2003).
However, screening for these mutations is only an assessment of risk, and does not
provide a diagnosis o f ovarian cancer.
Due to the limited ability o f all of these methods to effectively diagnose ovarian
cancer at early stages, only 19% o f new ovarian cancer cases are diagnosed at early
stages when tumours are still localized to the ovary, whereas approximately 70% o f new
ovarian cancer cases are diagnosed at advanced stages when the cancer has already
metastasized outside o f the ovaries to distant sites within the peritoneal cavity (Jemal,
Siegel et al. 2008). Unfortunately, once ovarian cancer has metastasized outside of the
ovaries, standard therapies are much less effective. This can be seen by the fact that
although the five-year survival rate for ovarian cancer patients who are diagnosed with
early localized disease is 92%, it decreases to 30% in patients who are not diagnosed until
the cancer has metastasized to distant sites outside o f the ovaries. High mortality in
ovarian cancer has also been partly attributed to having one of the highest average ages at
initial diagnoses, with a median age of 63 years (Ozols, Bookman et al. 2004). As a result
o f the current limitations relating to early ovarian cancer detection and the high mortality

associated with these limitations, it is essential to develop better early detection and
screening methods, as well as prevention strategies. One way that this may eventually be
achieved is by gaining a thorough understanding o f the molecular mechanisms and
factors that are essential to the development o f ovarian cancer.

1.1.3

Origins of ovarian cancer
Epithelial ovarian cancer (EOC) accounts for approximately 90% of all human

ovarian malignancies, and is believed to originate from the ovarian surface epithelium
(OSE) (Auersperg, Wong et al. 2001). However, there is also recent evidence to suggest
that EOC may have alternative origins in the fallopian tubes, which are in close proximity
to the ovaries (Medeiros, Muto et al. 2006; Levanon, Crum et al. 2008; Karst and
Drapkin 2010). Germ cell ovarian cancers account for 5% of human ovarian
malignancies, and stromal cell origins account for the remaining 5% o f ovarian cancers
(Shield, Ackland et al. 2009). The OSE consists of a single layer o f flat-to-cuboidal
mesothelial cells with few distinguishing features, and is separated from the stroma of the
ovary by an intermediate basement membrane (Auersperg, Wong et al. 2001).
Functionally, the OSE is responsible for the transportation o f molecules to and from the
peritoneal cavity, and is also involved in the processes of ovulatory rupture and
subsequent repair.
Although the etiology o f ovarian cancer is not completely understood, there are
several theories that have attempted to explain why EOC may originate from the OSE,
which are centered around data indicating that the risk o f an individual developing EOC
positively correlates with their number of lifetime ovulatory events (Ozols, Bookman et
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al. 2004). The best supported theory over the past several decades relating to this data is
the incessant ovulation hypothesis (Fathalla 1971). This hypothesis suggests that the
repetitive rupturing of the OSE that occurs during ovulation results in rapid cell
proliferation during postovulatory repair. The repetition o f this process over time may
lead to mutations in OSE cells, which could eventually lead to the formation o f tumour
cells. The second common hypothesis is the gonadotropin hypothesis (Ozols, Bookman
et al. 2004). It suggests that the increases in pituitary gonadotropins at the start of each
ovulation and that can persist for years after menopause can stimulate OSE cells in
inclusion cysts within the ovary, which may lead to mutations in OSE cells (Konishi,
K urodaetal. 1999).
There have also been recent studies suggesting alternative origins o f EOC other
than the OSE. For example, it has been suggested that high grade serous ovarian
carcinomas may originate from the fallopian tubes. This is based partly on observations
that ovarian carcinomas have little resemblance to OSE cells, and instead have a closer
resemblance to the epithelium o f the fallopian tube (Levanon, Crum et al. 2008).
Additionally, studies have examined the ovaries and fallopian tubes of BRCA1+women
at high risk for ovarian cancer who had bilateral salpingo-oophorectomies. Upon
examination, it was found that early stage serous carcinomas were found in several
patients in sections o f the fallopian tubes, whereas none were found in the ovaries
(Medeiros, Muto et al. 2006). Therefore, it is suggested that since the fallopian tube and
particularly the fimbria have a close proximity to the ovaries and are exposed to the same
microenvironment, transformed fallopian tube epithelial cells may shed into the
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peritoneal cavity or migrate to the ovaries during the early stages of cancer progression
(Karst and Drapkin 2010).

1.1.4

Subtypes of epithelial ovarian cancer
There are several subtypes o f epithelial ovarian cancer that can be distinguished

upon initial diagnosis based on tumour cell morphology. The four most common
histological subtypes o f ovarian cancer are serous, clear cell, endometrioid, and mucinous
carcinomas (Cho and Shih Ie 2009). Each of these subtypes is unique in terms of
incidence, genetic mutations, appearance, and response to treatment. Serous carcinomas
account for approximately 70% o f all EOC cases, clear cell account for 10%,
endometrioid account for 7%, and mucinous account for 3%. Additionally, serous
carcinomas are further classified into high-grade serous and low grade serous, with highgrade serous accounting for over 90% o f serous carcinomas.
Each subtype of ovarian cancer also has characteristic mutations that are
frequently associated with it. For example, high-grade serous carcinomas often have
BRCA1 or BRCA2 and TP53 mutations (Gilks and Prat 2009), low-grade serous
carcinomas are associated with BRAF or KRAS mutations, and clear cell carcinomas
frequently have PIK3CA mutations. As well, endometrioid carcinomas have the highest
frequency o f CTNNB1 mutations, and mucinous carcinomas are often associated with
mutations in KRAS (Cho 2009; Gilks and Prat 2009). With respect to prognosis, highgrade serous and clear cell are usually associated with a very poor prognosis, while
endometrioid and mucinous are generally associated with more favourable outcomes
relative to high-grade serous (Gilks and Prat 2009).
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1.1.5

Progression of epithelial ovarian cancer
During the early stages o f EOC progression, tumours are confined to either one,

or both ovaries (Naora and Montell 2005) (Figure 1.1). The canonical method of
epithelial cancer metastasis involves the escape o f cells from the primary tumour and the
intravasation o f these cells into the bloodstream, where they travel through the circulation
and extravásate to metastasize at secondary sites (Chambers, Groom et al. 2002).
However, unlike most other carcinomas, metastasis of EOC cells through the
bloodstream is rare (Allen, Porter et al. 1987). Instead, malignant cells are shed from the
primary tumour directly into the peritoneal cavity as EOC progresses. These cells can
then exist individually, or as multi-cellular aggregates of EOC cells called spheroids.
Individual cells and spheroids are both capable o f seeding metastases (Zietarska,
Maugard et al. 2007), but spheroid formation is hypothesized to be an intermediate
survival mechanism for EOC cells during dissemination (Shield, Ackland et al. 2009).
Once they are shed, EOC cells are transported by peritoneal fluid, and directly
disseminate throughout the abdominal cavity where they can metastasize to form
secondary tumours at regional and distant sites (Naora and Montell 2005). Common sites
of metastasis within the abdominal cavity include the uterus, fallopian tubes, omentum,
and the diaphragm.
Additionally, the formation o f ascites fluid within the abdominal cavity is usually
associated with this process of peritoneal dissemination (Naora and Montell 2005). The
buildup o f this fluid contributing to the transportation o f EOC cells is thought to be a
combination o f several factors including blockage o f the lymphatic system that results in
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Figure 1.1

Epithelial ovarian cancer metastasis and progression

As ovarian cancer progresses, (A) malignant cells shed from the surface of the ovaries
directly into fluid within the peritoneal cavity. These cells can either exist as individual
cells, or can aggregate to form spheroids. The individual cells or spheroids will then be
transported by ascites fluid throughout the peritoneal cavity where they (B) can form
secondary métastasés at sites such as the fallopian tubes and omentum (A- adapted from
Shield, K. et al. 2009, B - adapted from Naora, H. and D.J. Montell 2005).
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decreased fluid drainage, and the production of excess fluid due to inflammation within
the abdominal cavity.
The mechanisms that control this process of ovarian tumour cell dissemination
have not been well elucidated, and likely involve a number o f different signaling
pathways. Recently, one such pathway that has been implicated in EOC pathogenesis is
governed by the bone morphogenetic proteins (BMPs) (Shepherd and Nachtigal 2003).

1.1.6

Treatment of ovarian cancer
The standard treatment for ovarian cancer usually involves cytoreductive

debulking surgery in combination with adjuvant chemotherapy (Mutch 2002). The
objectives o f cytoreductive surgery are to reduce tumour burden, determine staging, and
to determine histological subtype. The reduction o f initial tumour burden is very
important in ovarian cancer because it is associated with survival advantages. This is seen
by the fact that patients with residual tumours that are less than 2 cm have an average
survival time of 40-45 months, whereas patients with residual tumours that are greater
than 2 cm have an average survival time o f only 12-16 months. After cytoreductive
surgery, patients are usually treated with intravenous combination chemotherapy of a
platinum as well as a taxane-containing agent, which is usually carboplatin-paclitaxel
(Gardner and Jewell 2011). However, the majority o f patients will recur within 18
months (Han, Lin et al. 2009). Recently, phase III clinical trials suggest that
intraperitoneal administration of platinum-taxane chemotherapy may be more effective
that intravenous administration (Armstrong, Bundy et al. 2006). As well, neoadjuvant
chemotherapy can also be administered to patients prior to optimal debulking surgery
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(Bilici, Salepci et al. 2010). The purpose o f administering chemotherapy before surgery is
to reduce tumour burden in order to increase the likelihood of optimal surgical debulking
and therefore increase median survival time.
The buildup o f ascites fluid is another symptom of ovarian cancer that needs to be
considered in ovarian cancer treatment. This is because recurrent malignant ascites can
cause painful and unpleasant symptoms that decrease the quality of life of patients, and
can also cause serious complications such as bowel perforation in extreme cases (Jatoi,
Giordano et al. 2005). Therefore, repeated paracentesis of ascites fluid from the
abdominal cavity may be required as often as every 9-10 days (Mackey and Venner
1996) in order to minimize these symptoms and complications.
Currently, the major focus o f clinical trials for ovarian cancer treatment involves
targeted biologic agents. For example, poly ADP ribose polymerase (PARJP) inhibitors
such as Olaparib are currently in phase II clinical trials (Audeh, Carmichael et al. 2010).
As well, the anti-angiogenic agent Bevacizumab that targets the vascular endothelial
growth factor (VEGF) pathway has demonstrated response benefits to treatment in phase
III clinical trials (Jelovac and Armstrong 2011).

1.2

The bone morphogenetic protein signaling pathway

1.2.1

Organization of the bone morphogenetic protein signaling family
The transforming growth factor (3 (TGFP) signaling pathway superfamily is

involved in diverse cellular processes including developmental processes, adult tissue
homeostasis, and also plays complex roles in many diseases (Moustakas and Heldin
2009). For example, misregulation o f this pathway can result in tumour development
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(Massague 2008). The human TGF|3 family consists of 33 members, which are
subdivided into families (Moustakas and Heldin 2009). These are the TGFp, growth and
differentiation factor (GDF), activins, nodal, and BMP families of ligands. The BMP
family is the largest subgroup within the TGFp superfamily o f ligands, and contains over
20 members that have been identified in humans (Blitz and Cho 2009).
Based on their sequence similarities and functions, the BMPs are generally
divided into at least 4 groups. These groups are BMP 2/4, BMP 5/6/7/8a/8b, BMP 9/10,
and BMP 12/13/14 (Bragdon, Moseychuk et al. 2011). The BMPs were originally
identified for their ability to induce ectopic bone and cartilage formation (Blanco Calvo,
Bolos Fernandez et al. 2009). However, they are involved in many other processes such
as embryonic patterning and development, tissue homeostasis and regeneration, as well
as various diseases (Wagner, Sieber et al. 2010). For example, functions that have been
associated with BMP4 specifically include the formation of teeth, bones, limbs, lungs,
and eyes from the mesoderm (Thawani, Wang et al. 2010). Additionally, BMP4 is
involved in dorsal-ventral patterning and craniofacial development, as well as repairing
bone. Although there is a large degree o f diversity among the functions and expression
patterns o f the BMPs, there are many compensatory functional overlaps (Hebert,
Hayhurst et al. 2003). For example, it has been shown that BMP2 and BMP4 can
compensate for one another in some aspects of development such as with patterning of
the dorsal telencephalic midline that eventually gives rise to distinct structures in the
adult brain in mammals.
The BMPs are expressed in many tissues in human adults. For example, BMP4
has been shown to be expressed in skeletal muscle, brain, heart, kidney, lung, pancreas,
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liver, spinal cord, as well as several other tissues (Bragdon, Moseychuk et al. 2011). With
respect to the ovaries, BMP4 has been shown to be expressed in almost all major ovary
cell types including oocyte, granulosa, theca, and ovarian surface epithelium cells
(Erickson and Shimasaki 2003).

1.2.2

Activation and regulation of bone morphogenetic protein signaling
O f all o f the families within the TGFP superfamily, the BMP family is the most

complex with respect to how it is activated and modulated (Hebert, Hayhurst et al. 2003).
BMP signaling involves type I (ALK2, ALK3, ALK6) and type II (BMPRII)
transmembrane serine/threonine kinase receptors (Blanco Calvo, Bolos Fernandez et al.
2009). In the absence o f a signal, these receptors are separated in the plasma membrane.
The process o f BMP signaling begins when a BMP ligand binds to a BMPRII receptor
(Waite and Eng 2003) (Figure 1.2), which results in the recruitment of a type I receptor to
form a heteromeric complex. This causes the BMPRII receptor to transphosphorylate the
type I receptor at its glycine/serine-rich domain, which results in its activation. Once the
type I receptor is activated, it has the ability to bind to several intracellular proteins that
are responsible for transducing the signal to the nucleus, which are the Smad proteins.
The activated type I receptor subsequently phosphorylates BMP-specific receptoractivated Smads (R-Smads 1, 5, 8), which causes the R-Smad to dissociate from the
receptor complex into the cytoplasm. The phosphorylated R-Smads can then form homoor heterodimers, and then associate with a common mediator Smad (co-Smad4). Finally,
the activated R-Smad/Smad4 complex translocates to the nucleus, where it regulates the
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Figure 1.2

The bone morphogenetic protein signaling pathway

Activation of canonical Smad-dependent BMP signaling begins with the binding of BMP
ligands to transmembrane receptor complexes. This binding leads to BMP-specific RSmad phosphorylation, formation o f an R-Smad/co-Smad4 complex, and translocation of
this complex to the nucleus where it affects the expression o f different target genes
(adapted from Waite and Eng 2003).
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expression o f different target genes through interactions with transcription factors, co
repressor proteins, and co-activator proteins.
There are several levels at which BMP signaling can be regulated. One way to
control BMP signaling is through extracellular BMP antagonists such as Noggin,
Chordin, Gremlin, and BMPER (Gazzerro and Canalis 2006). These extracellular
antagonists bind to BMP ligands and prevent them from binding to type I and type II
receptors. As well, the synthesis o f these BMP antagonists is usually stimulated by BMP
signaling (Blanco Calvo, Bolos Fernandez et al. 2009), which suggests that there is
controlled maintenance, i.e. negative-feedback regulation, of the balance o f BMPs and
their antagonists. Each antagonist has different affinities for binding depending on the
BMP ligand, which allows for complementary functions. Another mechanism of
inhibiting BMP signaling is through inhibitory Smads 6 and 7 (Imamura, Takase et al.
1997). These Smads can bind to the type I receptor, and therefore compete with R-Smads
for activation. Smad6 can also bind to phosphorylated Smadl to prevent it from forming
a complex with Smad4. Another level o f regulation is the pseudoreceptor BMP and
activin receptor membrane bound inhibitor (BAMBI) (Blanco Calvo, Bolos Fernandez et
al. 2009). BAMBI is a transmembrane protein that is similar to type I receptors, and
therefore functions as a decoy receptor to limit signaling. BMP signaling can also be
regulated by Smad-ubiquitination regulatory factors 1 and 2 (Smurfl and Smurf2), which
can bind to Smads 1 and 5 in order to initiate proteasomal degradation (Izzi and Attisano
2004). Finally, transcriptional co-repressors in the nucleus can prevent the activation of
target genes by BMPs. For example, c-Ski is a transcriptional co-repressor that can be
incorporated into Smad DNA binding complexes, which prevents them from interacting
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with co-activators and initiating the transcription of target genes (Akiyoshi, Inoue et al.
1999).
Although these descriptions of BMP signaling involving the Smad proteins is the
canonical and most studied aspect o f the BMP signaling pathway, BMPs can also induce
Smad-independent signaling. For example, BMP signaling has been shown to induce p38
mitogen-activated protein kinase (p38 MAPK) phosphorylation (Nakamura, Shirai et al.
1999), extracellular signaling regulated kinase (ERK) activation (Montesano 2007), c-Jun
N-terminal kinase (JNK) activation (Hocevar, Brown et al. 1999), and protein kinase C
(PKC)-dependent pathway activation (Hay, Lemonnier et al. 2001). Conversely, the RSmads and Smad4 can be activated by kinases in other pathways such as Erkl and Erk2,
p38, and JNK (Blanco Calvo, Bolos Fernandez et al. 2009).
One o f the transcription factor families that has been established as BMPregulated target genes are the inhibitors o f DNA binding (ID) proteins, of which there are
4 known members o f this family (ID1-ID4) (Pesce and Benezra 1993). All of the ID
family members contain a highly conserved helix-loop-helix domain that mediates
physical interactions with basic helix-loop-helix (bHLH) transcription factors that control
gene expression (Benezra, Davis et al. 1990). Since the IDs do not have a DNA binding
domain, heterodimeric complexes that are formed between the IDs and transcription
factors cannot bind DNA. Therefore, these proteins can have a significant regulatory
effect on gene expression. These proteins are known to play important roles in
embryogenesis and organogenesis (Lyden, Young et al. 1999), cell differentiation and
proliferation (Norton 2000), control of cell cycle progression, apoptosis (Norton and
Atherton 1998), and angiogenesis (Benezra, Rafii et al. 2001). As well, there are
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functional redundancies and some similar temporal and spatial expression patterns among
the 4 ID proteins (Norton 2000). In the adult, these proteins are expressed at low levels in
normal tissues, but their expression is often deregulated in tumours (Mem, Hasskarl et al.
2010). For example, the IDs have been shown to be upregulated in several human cancers
such ovarian (Shepherd and Nachtigal 2003), lung (Cheng, Tsai et al. 2011), prostate
(Forootan, Wong et al. 2007), and breast cancers (Yang, Liu et al. 2010).

1.2.3

Bone morphogenetic protein signaling in cancer
Although many o f the BMPs have been implicated in the promotion or inhibition

o f cancer development (Thawani, Wang et al. 2010), I will be focusing on studies
involving BMP4, and to a lesser extent, its subfamily member BMP2. There are several
lines of evidence in vitro and in vivo attributing pro-tumourigenic as well as antitumourigenic properties to BMP4 in numerous types of cancer. BMP4 is overexpressed
in many cancers such as melanoma (Rothhammer, Poser et al. 2005), hepatocellular
carcinoma (Maegdefrau, Amann et al. 2009), colon adenocarcinoma (Deng, Makizumi et
al. 2007), and multiple myeloma (Grcevic, Kusec et al. 2010). However, BMP4 has been
shown to exhibit decreased expression relative to normal tissues in cancers such as
prostate cancer (Spanjol, Djordjevic et al. 2010), and retinoblastoma (Haubold, Weise et
al. 2010).
There is a large body o f evidence in vitro suggesting that BMP4 signaling
increases cancer cell proliferation, increases migration, increases invasion, decreases
apoptosis, and induces expression of EMT markers. Treatment of the human DAOY
cerebellar primitive neuroectodermal tumour medulloblastoma cell line with either BMP2
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or BMP4 induced an anti-apoptotic effect based on immunohistochemistry (Iantosca,
McPherson et al. 1999). In other studies, tissue sections o f osteosarcomas that were
removed from patients were evaluated to look at BMP2 and BMP4 expression (Arihiro
and Inai 2001). It was found that BMP2 and BMP4 expression strongly correlated with
the tendency of these tumours to metastasize to bone in patients. Abnormal duct
organization and ductal lumen obliteration represent some o f the early stages of breast
cancer progression. When mouse J3B1A mammary epithelial cells were treated with
BMP4, they were unable to form any recognizable ductal lumen, thus contributing to the
tumourigenic progression of these cells (Montesano, Sarkozi et al. 2008). Another study
using J3B1A cells has shown that treatment with BMP4 significantly increases
proliferation (Montesano 2007). Similarly, GH3 prolactinoma cells that were treated with
BMP4 exhibited increased cell proliferation (Paez-Pereda, Giacomini et al. 2003). The
expression of c-Myc oncoprotein was also increased in these BMP4-treated GH3 cells,
while treatment with the BMP inhibitor noggin decreased proliferation and expression of
c-Myc. In human LAPC-4 and LAPC-9 prostate cancer cells, treatment with noggin
resulted in decreased cell migration (Feeley, Gamradt et al. 2005). A study involving NCI
H929 and Thiel human myeloma cell lines investigated the role of BMP4 signaling in
apoptosis (Grcevic, Kusec et al. 2010). These cell lines were treated with the proteasome
inhibitor Bortezomib alone or in combination with BMP4. Results demonstrated that cells
treated with BMP4 were partially protected from the apoptotic effects induced by
Bortezomib. BMP4 also has an important role in tumourigenesis in hepatocellular
carcinoma (HCC). The HepG2, Hep3B, and PLC human HCC cell lines in addition to
primary human HCC cells isolated from patients were transfected with antisense BMP4
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expression plasmids or siRNA against BMP4 (Maegdefrau, Amann et al. 2009).
Knockdown of BMP4 resulted in a decrease in both cell migration and invasion through
Matrigel. With respect to the Panc-1 human pancreatic cancer cell line, treatment with
BMP4 induces epithelial-mesenchymal transition (EMT) (Hamada, Satoh et al. 2007).
This was seen by the fact that these treated cells exhibited decreased expression of Ecadherin, and increased expression of vimentin. It was suggested that these effects on
EMT induction are mediated through an increase in homeobox gene transcription factor
MSX2 expression. MSX2 has been previously shown to be a target gene of BMP
signaling (Hussein, Duff et al. 2003), and enhances EMT in pancreatic cancer cells
(Satoh, Hamada et al. 2008). Additionally, these BMP4-treated Panc-1 cells had
enhanced cell motility (Hamada, Satoh et al. 2007). HCT116 human colorectal cancer
cell line clones have also been transfected with BMP4 over-expression plasmid (Deng,
Makizumi et al. 2007). These BMP4 overexpressing clones show increased resistance to
serum-starving induced apoptosis (Deng, Makizumi et al. 2007). These cells also
displayed enhanced migration and invasion through Matrigel. Noggin treatment reversed
all of these tumourigenic effects in HCT116 cells. Another study examining human
colorectal cancer by using the SW480 cell line shows that the stable transfection of
BMP4 plasmid in these cells results in the upregulation of vimentin expression (Deng,
Ravikumar et al. 2009).
These pro-tumourigenic effects o f BMP signaling have also been assessed in vivo.
For example, GH3 prolactinoma cells that were stably transfected with noggin and
injected into nude mice formed tumours that were smaller based on volume, and these
tumours also had reduced c-Myc oncoprotein expression (Paez-Pereda, Giacomini et al.

2003). Additionally, studies subjected SCID mice to tibial injections with LAPC-9
prostate cancer cells that were transduced with retrovirus that contained noggin-cDNA
(Feeley, Gamradt et al. 2005). Mice that were injected with these noggin-overexpressing
LAPC-9 cells formed significantly smaller osteoblastic lesions when viewed on
radiographs (Feeley, Gamradt et al. 2005).
There is a growing body o f evidence in vitro suggesting that the BMPs,
particularly BMP4, play important roles as tumour suppressors. For example, treatment
with BMP2 or BMP4 inhibits proliferation of mouse cerebellar granule neuron progenitor
(GNP)-like medulloblastoma cells (Zhao, Ayrault et al. 2008). The effects of BMP2 and
BMP4 treatment have also been evaluated in primary human glioblastoma (GBM) cells.
Treatment with BMP2 or BMP4 did not induce cell death or apoptosis in vitro in these
cells (Piccirillo, Reynolds et al. 2006). However, BMP4 treatment, and to a lesser extent
BMP2 treatment, significantly decreased the proliferation of GBM cells. Relative to nontreated cells, BMP treatment also led these cells to become more differentiated as seen by
cell morphology and increases in the fluorescence signaling intensity of glial fibrillary
acidic protein (GFAP). In another study, human glioma U251 cells that were transfected
with BMP4 plasmid exhibited decreased proliferation (Liu, Tian et al. 2010). Upon
BMP4 treatment o f 9 different breast cancer lines, all cell lines exhibited significant
growth inhibition relative to vehicle-treated cells (Ketolainen, Alarmo et al. 2010)
(Ketolainen, Alarmo et al. 2010). Another study that investigated the relationship
between BMP signaling and breast cancer used MDA-MB-231 breast cancer cells, and
treatment o f these cells with BMP4 resulted in a significant decrease in the migratory and
invasive abilities o f these cells (Shon, Kim et al. 2009). These effects were likely
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mediated through decreased mRNA expression of matrix metalloproteinase 9 (MMP 9),
which is an enzyme that is in part responsible for the degradation of surrounding
extracellular matrix components during invasion and metastasis. Treatment of human
A549 epithelial ling cancer cells with BMP4 led to a more senescent phenotype (Buckley,
Shi et al. 2004). In another study involving A549 lung cancer cells, BMP4-treatment led
to decreased p-ERK and Bcl2, supporting decreased proliferation and increased potential
for apoptosis, as well as decreased invasiveness. Similarly, studies with siRNA-mediated
knockdown of BMP4 in A549 and NCI-H460 non-small cell lung cancer cells showed
increased proliferation, as well as decreased senescence (Su, Zhu et al. 2009). Treatment
with exogenous BMP4 decreased proliferation and increased apoptosis in ANBL-6, OH2,
and IH1 human myeloma cell lines (Hjertner, Hjorth-Hansen et al. 2001). In this same
study, freshly isolated primary multiple myeloma cancer cells from several patients that
were immediately treated with BMP4 exhibited increased apoptosis. Treatment of 8
retinoblastoma cell lines with recombinant human BMP4 results in an increase in
apoptosis (Haubold, Weise et al. 2010). Also, primary human basal cell carcinoma (BCC)
cells that were isolated from patient tumours and subsequently treated with recombinant
human BMP4 exhibited decreased cell proliferation (Sneddon, Zhen et al. 2006).
Similarly, primary human BCC cells in this study that were treated with recombinant
mouse BMP inhibitor Gremlin-1 exhibited increased cell proliferation. Using human
AtT-20 pituitary corticotroph tumour cells, it was shown that treatment with BMP4
inhibited cell proliferation (Giacomini, Paez-Pereda et al. 2006). Finally, human
NTERA2 teratocarcinoma cells that were treated with exogenous BMP4 exhibited a
decrease in cell proliferation and increased apoptosis (Nishanian, Kim et al. 2004).
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There has also been a small number of studies in vivo supporting BMP signaling
as an anti-tumourigenic pathway. For example, mouse cerebellar GNP-like
medulloblastoma cells were transfected with BMP4 and were allografted into
immunocompromised athymic mice (Zhao, Ayrault et al. 2008). Tumours formed in these
mice were much smaller than allografts o f cells transfected with a control vector. When
BMP4-saturated polyacrylic beads where co-injected with GBM cells into mice, the mice
developed smaller, more confined lesions, and survived for a significantly longer period
of time compared to controls (Piccirillo, Reynolds et al. 2006). Another study showed
that BMP4-treated A549 cells that were injected into nude mice formed much smaller
tumours based on volume (Buckley, Shi et al. 2004). Also, stably transfecting human
AtT-20 pituitary corticotroph tumour cells with expression vectors for noggin or a
dominant-negative form of BMP4 and injecting them into nude mice corresponded to
increased tumourigenicity as measured by tumour volume (Giacomini, Paez-Pereda et al.
2006). Finally, BMP4-treated human NTERA2 cells that were injected into
immunodeficient mice formed smaller tumours relative to controls based on tumour
volume (Nishanian, Kim et al. 2004).
BMP4 has recently been shown to have an effect on cancer stem cells, or cancer
initiating cells. One study used primary colorectal cancer stem cells (CRC-SCs) that were
selected from primary patient tumour samples based on CD 133 expression (Lombardo,
Scopelliti et al. 2011). Although BMP4 is usually expressed in colorectal cancer, it was
not detected in the CRC-SCs (Lombardo, Scopelliti et al. 2011). In vitro, CRC-SCs form
spheres o f aggregated cells, whereas differentiated colorectal cancer cells lack this
ability. Treatment of CRC-SCs with exogenous BMP4 induced cell differentiation based
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on immunohistochemical staining for the expression of CK20+ cells. Phase contrast
microscopy also confirmed that these cells differentiated as evidenced by larger,
polygonal colon cells. The effect of BMP4 treatment on CRC-SC response to
chemotherapy was also evaluated. Tumours that were formed in immunocompromised
mice by CRC-SC sphere injections were treated with oxaliplatin and 5-fluorouracil (5FU) alone or in combination with BMP4-loaded heparin acrylic beads. Combination
treatment with BMP4 sensitized the tumours to chemotherapy as measured by tumour
size after treatment. Also, another study investigated the role of BMP4 in brain tumourinitiating cells (BTICs) o f human GBMs (Piccirillo, Reynolds et al. 2006). Treatment of
primary adult human GBM cells with exogenous BMP4 significantly reduced the pool of
BTICs by approximately 50% in GBM cell populations as measured by sorting for
CD133+ cells from culture.
Overall, these differing and often contrasting reports on the numerous roles of
BMP4 in cancer highlight the fact that BMP signaling may have unique roles in the
process o f tumourigenesis on a cancer-specific basis. Additionally, BMP signaling may
have different roles even within the same type o f cancer depending on the stage of the
disease. Therefore, it is essential to study the roles of BMP4 signaling in an EOC-specific
context.

1.2.4

Bone morphogenetic protein signaling in ovarian cancer
It has been shown that immortalized normal OSE cells, ovarian cancer cell lines,

primary normal OSE cells, and primary EOC cells all express BMP4 mRNA (Shepherd
and Nachtigal 2003). However, BMP2 was expressed in a smaller number of samples,
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and BMP7 was not expressed in any sample. Mature BMP4 protein was also expressed in
primary EOC cells as measured by immunoprécipitation of 35S-Met/Cys radiolabeled
BMP4 proteins that were secreted by cells into culture medium. Additionally, all of the
samples expressed the intracellular components that are necessary for a functional BMP4
signaling pathway based on mRNA expression. These included type II BMP receptors, as
well as type I BMP ALK3 receptors. Type I BMP ALK6 receptors were expressed in the
EOC cell lines, but expression was very weak or absent in the primary and immortalized
cells. In addition, each group o f cells expressed co-Smad4, and R-Smads 1, 5, and 8.
Not only are components of BMP4 signaling present in EOC and OSE cells, but
the pathway is also functional (Shepherd and Nachtigal 2003). This was assessed by
treating cells in vitro with recombinant human BMP4. BMP4 treated cells expressed
increased phospho-Smadl and had enhanced nuclear localization of phospho-Smadl
based on indirect immunofluorescence. BMP-regulated target genes Smadô, Smad7, ID1,
and ID3 RNA were all induced by BMP4 treatment. Interestingly, ID1 and ID3
expression were induced approximately 5 fold more in BMP4-treated primary EOC cells
relative to induction in BMP-treated normal OSE cells. A similar study has shown that
treatment of CaOV3 human ovarian cancer cells with noggin resulted in a decrease in
endogenous ID3 mRNA expression in a dose-dependent manner (Shepherd, Theriault et
al. 2008). However, treatment o f these cells with broader BMP inhibitors that have a
weaker affinity for BMP4 did not significantly change ID3 expression, which suggests
that ID3 overexpression in human EOC is controlled primarily by autocrine BMP4
signaling.
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The CaOV3 and SkOV3 human ovarian cancer cell lines in addition to primary
EOC cells that were isolated from ascites fluid were all treated with recombinant human
BMP4. With respect to proliferation, BMP4 treatment had no effect (Shepherd and
Nachtigal 2003). However, BMP4 treatment led to changes in cell morphology that
resembled cell spreading and cells appeared more flattened as opposed to the epitheliallike cobblestone morphology that was representative of untreated cells (Shepherd and
Nachtigal 2003; Theriault, Shepherd et al. 2007). As well, primary human ovarian cancer
cells and normal OSE cells were treated with human recombinant BMP4 or transduced
with an adenovirus expressing constitutively active ALK3 (ALK3QD). These cells were
significantly larger in size with respect to area relative to untreated cells based on phasecontrast images (Theriault, Shepherd et al. 2007). One of the functional implications of
this cell spreading morphology was seen by the fact that BMP4 treatment led to
decreased cell detachment in vitro (Shepherd and Nachtigal 2003). Additionally, primary
EOC cells that were treated with BMP4 or transduced with ALK3QD showed increased
motility (Theriault, Shepherd et al. 2007). Conversely, treatment o f these cells with
noggin decreased cell motility. However, treatment of normal OSE cells with BMP4 did
not affect motility, which suggests that EOC cells have enhanced their motility in
response to acquired autocrine BMP signaling. As well, primary EOC cells that were
transduced with ALK3QD exhibited an increase in invasive potential in vitro. After
BMP4 treatment, primary EOC cells exhibited increased expression of Snail and Slug
protein. These EMT marker proteins are known to repress E-cadherin (Batlle, Sancho et
al. 2000), which exhibited decreased protein expression in BMP4 treated cells. This
suggests that BMP4 can induce EMT in primary EOC cells (Theriault, Shepherd et al.
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2007). Another study has shown that chordin is underexpressed in EOC tumour samples
relative to normal ovarian tissue at the mRNA level (Moll, Millet et al. 2006). After this
discovery, BG1 and PE014 human ovarian cancer cell lines were transiently transfected
with an expression vector for chordin. This chordin overexpression decreased the
migration and invasion capabilities o f these cells. Additionally, chordin treatment
increased the adhesion o f EOC cells.
Studies have also implicated BMP signaling in decreasing metastatic potential in
ovarian cancer. For example, OVCA429 human ovarian cancer cells were transfected for
doxycycline-inducible expression of constitutively-active ALK3QD in order to evaluate
the role of BMP signaling in ovarian cancer metastasis (Shepherd, Mujoomdar et al.
2010). Xenografts of these OVCA429 ALK3QD induced clones into athymic nude mice
resulted in decreased tumour implantation on peritoneal surfaces. As well, these mice
exhibited a decrease in ascites formation. A potential underlying basis for this decrease in
metastatic potential was that pi-integrin and p3-integrin mRNA expression was
decreased in ALK3QD-expressing cells. These integrin proteins are essential for cell
adhesion, and in fact, ALK3QD-expressing cells exhibit reduced cell adhesion to
fibronectin and vitronectin in vitro. Additionally, OVCA429 ALK3QD-expressing cells
had reduced cell cohesion based on their decreased ability to form spheroids in ultra-low
attachment plates as measured by decreased size and density of the spheroids in culture.
Overall, this paper suggested that although upregulated BMP signaling is advantageous
for cells to lose adhesion and exfoliate from the primary tumour, decreased BMP
signaling may be important for cells to metastasize and adhere to secondary tumour sites.
In an expression study involving BMP2, it was shown that this protein in addition to
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BMPR1B and BMPRII was expressed at lower levels in ovarian cancer tumours
compared to normal ovarian tissue (Ma, Ma et al. 2010). Additionally, retrospective
analyses were completed in which tumour sections obtained from patients were stained
for BMP2 and evaluated using immunohistochemistry. A correlation was found
suggesting that patients with positive expression of BMP2 in tumours had a significantly
increased average 5-year survival rate relative to patients with tumour samples that did
not stain for BMP2. Studies investigating the role o f BMP signaling in ovarian cancer
have also focused on antagonists o f this pathway. For example, SKOV3 human ovarian
cancer cells were transfected with a vector expressing BAMBI, which is a BMP type I
pseudoreceptor (Pils, Wittinger et al. 2010). Upregulated BAMBI expression in these
cells led to increased cell proliferation as measured in vitro.
Human ovarian carcinoma-associated mesenchymal stem cells (CA-MSCs) have
recently been identified and characterized (McLean, Gong et al. 2011). Upon
subcutaneous injections of human ovarian cancer SKOV3 cells alone or in combination
with either CA-MSCs or healthy donor MSCs into immune-compromised mice, co
injection with CA-MSCs significantly increased tumour size based on weight. As well,
culturing ovarian tumour cells in the presence of CA-MSCs resulted in the tumour cells
forming large spheroids in vitro, which is associated with cancer stem cells (CSCs)
(Ernst, Hofmann et al. 2009). Interestingly, BMP2 and BMP4 mRNA were significantly
upregulated in all human CA-MSC samples (McLean, Gong et al. 2011). Inhibition of
BMP signaling with noggin decreased tumour spheroid formation, and prevented CAMSC cells from stimulating ovarian tumour growth in mice.
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1.2.5

Bone morphogenetic protein signaling and angiogenesis
Angiogenesis is one o f the hallmarks o f cancer along with uncontrolled

proliferative signaling, reprogramming o f energy metabolism, evasion of growth
suppression, resistance to cell death, evasion of immune destruction, replicative
immortality, and the activation o f invasion and metastasis capabilities (Hanahan and
Weinberg 2011). In addition to normal tissues, tumours require access to a blood supply
in order to receive oxygen and nutrients, and to excrete waste products and carbon
dioxide. During embryonic development, blood vessels can form through one of two
processes (Hanahan and Folkman 1996). The first process is vasculogenesis, which
involves the formation of new blood vessels through the creation o f new endothelial cells
from progenitor cells. The second process is angiogenesis, which involves the sprouting
of new capillaries from pre-existing blood vessels. In the adult, new blood vessel
formation is accomplished predominantly through the process o f angiogenesis.
With the exception o f transient processes such as wound healing and the female
reproductive cycle, vasculature in the adult is usually in a quiescent state (Hanahan and
Weinberg 2011). However, the vasculature remains activated during tumour development
throughout the process of angiogenesis in order for tumours to be able to survive and
grow beyond 1-2 mm in diameter (Bergers and Benjamin 2003). This change in
vasculature activity is termed the angiogenic switch, which describes a change in the
balance between angiogenic promoters such as VEGF, and angiogenic inhibitors such as
thrombospondin-1 (TSP-1) (Hanahan and Folkman 1996).
Interestingly, the blood vessels that are formed by angiogenesis during
tumourigenesis differ from blood vessels formed under normal conditions because they
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are irregularly shaped and disorganized, unusually large, have extensive branching, and
display leakiness (Nagy, Chang et al. 2010). Briefly, this process of angiogenesis in
tumours begins with endothelial cells releasing factors that degrade the basement
membrane o f the vessel walls (Hanahan and Folkman 1996). The endothelial cells near
this area of membrane degradation then invade the surrounding stroma and proliferate as
a migrating column. Then, these endothelial cells will strop proliferating and differentiate
so that they are able to tightly adhere to each other and form a new capillary tube.
The BMP signaling pathway has been shown to be essential in the processes of
vasculogenesis and angiogenesis, with BMP2 and BMP4 appearing to be the most
important members of the BMP family in this process as evidenced by mouse knockout
models (Moser and Patterson 2005). Mouse embryos with inactivated BMP4 display
defects in mesoderm formation, which is required for vascular development, and most
mice die around embryonic day (E)7.5 (Winnier, Blessing et al. 1995). Some of these
mice survive until approximately E9.5, but eventually die and exhibit abnormal
vasculature with a reduced number of blood islands. ALK2-deficient mouse embryos die
early in development with severe disruption of mesoderm formation that is essential in
the formation o f mature vasculature (Gu, Reynolds et al. 1999). ALK3-deficient mouse
embryos exhibit similar characteristics, and die early in development due to a lack of
mesoderm formation (Mishina, Suzuki et al. 1995). As well, mice with heterozygous
inactivating mutations of BMP type 2 receptor have an impaired ability to remodel
vasculature in response to exposure to prolonged hypoxia (Beppu, Ichinose et al. 2004).
The Smads have also been shown to play an important role in angiogenesis during mouse
embryonic development. For example, Smadl null mice die during gestation in part due

to vascular disorganization (Lechleider, Ryan et al. 2001), and mice in which Smad5 is
inactivated die during gestation due to vasculature defects and irregular distribution of
blood cells (Yang, Castilla et al. 1999). Additionally, Smad4 deficient mice die by E6.5
due to a lack of mesoderm formation (Sirard, de la Pompa et al. 1998). Transcription
factors that are targeted by BMP signaling have also been investigated in knockout mice.
For example, double knockout ID F'' ID3'/_ mice die before E l3.5 (Lyden, Young et al.
1999). Blood vessels in these mice are unable to branch or sprout into the neuroectoderm,
and also have defects in the vasculature within the forebrain.
It has been shown both in vitro and in vivo that human endothelial cells involved
in blood vessel formation possess an intact and functional BMP signaling pathway, and
there is direct evidence that BMP signaling plays a role in the process o f angiogenesis
(Valdimarsdottir, Goumans et al. 2002). Using Matrigel tube formation angiogenesis
assays with human microvascular endothelial cells (HMECs), it was shown that BMP4
enhanced angiogenesis (Rothhammer, Bataille et al. 2007). In mouse osteoblast cells,
exogenous treatment o f BMP4 in vitro induced angiogenesis due to an increase in VEGFA protein production (Deckers, van Bezooijen et al. 2002). However, BMP4-induced
angiogenesis treatment was abrogated when VEGF-A antibody was added to these
osteoblast cells, suggesting that BMP4-induced angiogenesis is mediated in part by
VEGF-A. Ectopic BMP4 signaling in zebrafish embryos induced the expression of
VEGF and VEGF receptor 2 mRNA in embryonic endothelial and blood precursor cells
(He and Chen 2005). As well, treatment o f human retinal pigment epithelial cells with
BMP4 led to an increase in VEGF secretion in a dose and time-dependent manner (Vogt,
Unda et al. 2006). Transient transfections of endothelial cells from human colon, mouse

aorta, and mouse heart with constitutively-active ALK3, Sm adl, or Smad5 were shown
to stimulate cell migration and tube formation (Valdimarsdottir, Goumans et al. 2002).
Interestingly, ectopic expression of Idl also stimulated tube formation, while treatment
with antisense Idl blocked the BMP-induced effects on tube formation. Other than VEGF
and Idl, relatively little is known about downstream target genes that are affected by
BMP signaling that have a role in angiogenesis (Ren, Charles et al. 2007). Recently, gene
expression profiling o f BMP-treated mouse intraembryonic endothelial cells highlighted
Cox2 as a gene that is strongly upregulated by BMP stimulation. Inhibition of Cox2
blocked the BMP-induced increases in endothelial cell proliferation and tube formation.
Similar microarray studies have also shown that MyolO is strongly upregulated in BMPtreated mouse endothelial cells, with inhibition of MyolO decreasing BMP-induced tube
formation on Matrigel (Pi, Ren et al. 2007).
Although these studies highlight a role for BMP signaling in the activation of
angiogenesis, there are also several conflicting reports that implicate BMP signaling in
the inhibition o f angiogenesis. In a mouse model where retina were subjected to hypoxia
in order to stimulate neovascularization, BMP4-mRNA expression was drastically
decreased (Mathura, Jafari et al. 2000). Likewise, primary cultures of human retinal
pericytes exhibited increased expression of BMP4 antagonist chordin-like 1 mRNA in
response to hypoxia. Angiogenesis assays using human umbilical vein endothelial cells
(HUVECs) were done using exogenous BMP4 alone, exogenous chordin-like 1 alone, or
in combination. BMP4 treatment significantly inhibited angiogenesis (Kane, Godson et
al. 2008). While chordin-like 1 did not have a significant effect on its own, it modulated
the inhibitory effect o f BMP4 on angiogenesis when added in combination. BMP4
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signaling has also been implicated in studies in vivo looking at the process of
microvascular remodeling, which includes the formation o f new blood vessels as well as
the regression o f others. When BMP4 was injected transcomeally into postnatal day 8
rats, the number o f apoptotic endothelial cells was significantly increased in dissected
pupillary membranes (Kiyono and Shibuya 2003). Conversely, the addition of noggin or
BMP4-specific neutralizing antibody increased the number of surviving capillary cells by
4-6 fold. BMP4 has also been shown to induce apoptosis of primary human capillary
venous endothelial cells in a dose-dependent manner in vitro (Kiyono and Shibuya 2006).
However, human arterial endothelial cells were not affected by BMP4 treatment initially.
Interestingly, mRNA levels o f inhibitory Smads 6 and 7 were strongly correlated with
BMP4-induced apoptosis resistance in these cells, and knockdown of inhibitory Smad
expression with siRNA caused sensitization of endothelial cells to BMP4 stimulation.
BMP antagonists have also been implicated in angiogenesis. Increasing doses of
BMPER increased HUVEC sprouting, which was inhibited when BMPER was silenced
(Heinke, Wehofsits et al. 2008). These results were also confirmed with in vivo
experiments where BMPER protein addition to the surface o f the chick chorioallantoic
membrane (CAM) increased the density o f the capillary network and average diameter of
blood vessels. As well, using a subcutaneous mouse Matrigel plug assay, increased
BMPER enhanced endothelial cell invasion. Interestingly, BMPER lost its proangiogenic
capacity at higher concentrations both in vitro and in vivo, which suggests the presence of
a feedback mechanism to modulate endothelial cell functions in a dose-dependent
manner, or off-target effects such as the inhibition of additional low-affinity ligands.
Another BMP antagonist, Gremlin, has been shown to increase blood vessel formation in
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vivo when gelatin sponge implants containing Gremlin were placed on the surface of the
chick CAM (Mitola, Moroni et al. 2008). Specifically, Gremlin induces angiogenesis by
inducing angiopoietin-1 expression in endothelial cells through the activation of NF- kB.

1.2.6

Bone morphogenetic protein signaling and tumour angiogenesis
With respect to tumour growth, the BMPs have been implicated in enhancing

angiogenesis in several different types o f cancer. BMP2 has been the most extensively
studied with respect to the role of BMPs in angiogenesis and tumour formation
(Langenfeld and Langenfeld 2004; Raida, Clement et al. 2005; Bieniasz, Oszajca et al.
2009). For example, co-injection o f A549 lung cancer cells and recombinant BMP2 into
athymic nude mice resulted in the formation larger tumours that had a significant increase
in the number of blood vessels relative to control injections (Langenfeld and Langenfeld
2004). The inhibition of BMP2 signaling with noggin or BMP2 antisense
oligonucleotides resulted in decreased blood vessel formation in these tumours. Similar
effects o f BMP2 have been observed in breast cancer, as athymic nude mice that were
injected with BMP 2 stably-transfected MCF-7 human breast cancer cells exhibited
developed tumours with high vascularization (Raida, Clement et al. 2005). Furthermore,
it was shown in this study that BMP2 upregulates p38 MAPK phosphorylation and Idl
expression in HUVECs, which suggests potential mechanisms by which BMP2 can
achieve its effects on tumour angiogenesis. As well, it has been shown that BMP2 mRNA
is positively correlated with VEGF mRNA in lung cancer patients (Bieniasz, Oszajca et
al. 2009).
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BMP4 has also been shown to play a role in tumour angiogenesis. Mel Im
melanoma cells that were stably transfected with antisense BMP4 or noggin expression
vector had a decreased ability to induce endothelial cell tube formation (Rothhammer,
Bataille et al. 2007). As well, when these transfected cells were injected into athymic
nude mice, resultant tumours had a decrease in blood vessel density. In Hep3 human
HCC cells, BMP4 expression was significantly increased when hypoxia was induced in
vitro (Maegdefrau, Amann et al. 2009). Additionally, HCCs that were transfected with
siRNA against BMP4 and co-cultured with HMECs resulted in a significantly decreased
ability to induce angiogenesis.
The role o f the BMP signaling pathway has also been assessed indirectly in Id l+/"
Id3’/_ mice. In these mice, reduced Id expression resulted in small tumour growth from
injected breast cancer cells, and these tumours regressed within 2 weeks relative to the
much larger tumours that were formed in wild-type mice (Lyden, Young et al. 1999).
Tumour growth in Id l+/' Id3

was intermediate between wild-type and Id l+/' I d 3 m i c e ,

clearly indicating a dose-dependency o f Id protein function on tumour angiogenesis.
These results were consistent for injections of B6RV2 lymphoma cells, and B-CA breast
cancer cells into Id-deficient mice where differences in tumour growth were attributed to
poor vascularization due to decreased branching and sprouting o f blood vessels compared
to wild-type mice.
Due to numerous studies that have been discussed above implicating BMP
signaling in tumour angiogenesis, components of the BMP signaling pathway have been
established as potential targets for anti-angiogenic therapy in some cancers. For example,
the heparin sulfate proteoglycan mimetic drug WSS25 has been shown to inhibit human
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microvascular endothelial cell tube formation in Matrigel angiogenesis assays (Qiu, Yang
et al. 2010). Mechanistically, WS225 was shown to exert its effects by blocking
BMP2/Smad/Idl signaling. This result was confirmed in vivo, as WSS25 treatment of
nude mice that were injected with hepatocellular carcinoma cells exhibited decreased
tumour growth due to the inhibition of angiogenesis.
In rare instances, BMPs have been shown to either have no effect on
angiogenesis, or decrease angiogenesis in tumours. For example, there was no significant
difference in VEGF and IL-8 expression levels upon recombinant human BMP2
treatment o f UMSCC-1 and UMSCC-74A human oral squamous cell carcinoma (OSCC)
cells (Gao, Tong et al. 2010). This result was confirmed in vivo, as there was no
difference in blood vessel density o f OSCC tumours formed from cells that were infected
with adenovirus expressing BMP-2 before being injected into mice. Also, treatment of
A549 lung carcinoma cells with BMP4 in vitro led to decreased expression of VEGF
protein, which contributed to the formation o f smaller tumours that were formed in nude
mice (Buckley, Shi et al. 2004). Additionally, the BMP antagonist gremlin is believed to
play a pro-angiogenic role in specific cancers. For example, injection of human
adenocarcinoma HEC-l-B cells into nude mice showed very strong gremlin expression in
highly vascularized areas o f the tumour, whereas expression was much lower in other
parts of the tumour (Stabile, Mitola et al. 2007). Despite the fact that the majority of the
current literature supports the BMPs as pro-angiogenic factors with respect to
tumourigenesis, these examples o f BMPs having anti-angiogenic effects highlight the
importance o f studying BMP signaling relating to tumour angiogenesis in a cancerspecific context. Specifically, the role o f BMP signaling in angiogenesis has never been
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reported in EOC. Therefore, our findings will shed light on the potentially unique role of
BMP4 signaling on mouse EOC angiogenesis.

1.3

Models of cancer

1.3.1

Mouse models of epithelial ovarian cancer
Although there have been other animal models such as rat (Davies, Auersperg et

al. 1998), rabbit (Coppola, Saunders et al. 1999), and hen (Johnson 2009) models of
ovarian cancer, this discussion will focus on mouse models o f EOC. Historically, the
majority of animal models o f ovarian cancer have involved xenografting human ovarian
cancer cells into immunodeficient mice such as severe combined immunodeficient
(SCID) and athymic nude mice (Cho 2009). These xenografts have been administered by
subcutaneous implantation (Downer, Jones et al. 2001), intraperitoneal injections
(Shepherd, Mujoomdar et al. 2010), and by orthotopic implantations into the mouse
ovarian bursa (Greenaway, Henkin et al. 2009).
Alternatively, mouse cell lines were created from studies in which mouse ovarian
surface epithelial cells were passaged repeatedly in vitro. Late passage cells then
spontaneously transformed and were able to form ovarian tumours when injected into
both immunocompromised and immunocompetent mice (Roby, Taylor et al. 2000). From
this study, the spontaneously-transformed clone ID8 has been generated, which has been
shown to express constitutively active Src (Pengetnze, Steed et al. 2003). There is another
mouse ovarian cancer cell line that has been created by transfecting SV40 TAg into
primary cultures o f mouse ovarian surface epithelium (MOSE) cells, which were then
able to form tumours when injected into nude mice (Kido and Shibuya 1998). However,
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additional mouse EOC cell lines with specific and known mutations need to be created
and characterized so that they can be used in order to gain a more thorough understanding
o f EOC.
There have been some recently developed genetically engineered mouse models
o f EOC. One o f the first transgenic mouse models o f EOC was created by expressing the
early region o f the SV40 TAg gene, and placing it under the transcriptional control of the
MISRII (Müllerian inhibiting substance type II receptor) gene promoter (Connolly, Bao et
al. 2003). These TgMISIIR-TAg transgenic mice develop poorly differentiated ovarian
cancer that replicates several key features of human ovarian cancer progression such as
tumour dissemination and the formation o f ascites. Recently, there have been several
mouse models of ovarian cancer that rely on conditional expression of genes through
Cre-recombinase mediated excision o f specific sequences flanked by loxP sites
containing these genes (Connolly 2009). This is accomplished by locally administering
adenovirus that expresses Cre-recombinase to the mouse ovarian bursa. For example,
one study developed LoxP-Stop-LoxP-A>as 0120 ' Pten loxP/Loxf miCe with conditional
activation of Kras and conditional inactivation o f Pten, which was the first genetic mouse
model o f endometrioid EOC; a cell line developed from these mice will be discussed later
(Dinulescu, Ince et al. 2005). Another mouse model that develops tumours that are
histologically similar to endometrioid EOC is the Pten LoxP/LoxF Ape LoxP/LoxP mouse model
with conditional inactivation of the Pten and Ape genes (Wu, Hendrix-Lucas et al. 2007).
As well, p53 and Rb are conditionally-inactivated in p53 LoxP/LoxF Rfr loxP/loxh mjce? and
tumours that are formed in these mice resemble serous EOC (Flesken-Nikitin, Choi et al.
2003).
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Ideally, other in vivo model systems need to be used in order to complement
mouse EOC studies and address some o f the limitations of the current xenograft and
genetically-engineered mouse models. One such model that has rarely been used to study
EOC, but that offers many unique advantages, is the chick chorioallantoic membrane
(CAM) model system. I will discuss several characteristics o f this model system as well
as the few ovarian cancer studies that have utilized this system in order to highlight
several o f the unique advantages o f this model that can be utilized to study EOC.

1.3.2

Chick chorioallantoic membrane
In the developing avian embryo, the chick CAM is a specialized tissue that

functions as a lung for the embryo, as it is responsible for gas and nutrient exchange
between the embryo and the surrounding atmosphere (Deryugina and Quigley 2008).
Initially, the CAM is formed between days 5 and 6 of embryonic development due to the
partial fusion of chorion and allantois. It is a very thin structure that usually less than 100
pm in thickness once it is fully formed (Deryugina and Quigley 2008). Histologically, it
consists o f 3 main layers (Deryugina and Quigley 2008).The first layer is the ectoderm,
which is usually attached to the shell membrane and is one or two epithelial cell layers in
thickness. This layer eventually develops into the capillary plexus around day 10, which
is a network o f capillaries that connect arterial and venous blood vessel networks that
contribute to a highly vascularized tissue. The middle layer is the mesoderm that also has
many blood vessels, o f which some are terminal capillaries that end immediately below
the ectoderm. This layer also contains stromal components and collagen fibers. Finally,
the third and innermost layer is the one-cell layer thick flat endoderm, which separates
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the rest of the CAM from the allantoic cavity. Between days 10-15, there are 2 types of
inflammatory cells that can present themselves in the embryos (Deryugina and Quigley
2008). The first group is the heterophils, which are the avian equivalent to mammalian
neutrophils. The second group of inflammatory cells is the monocytes. Both of these
inflammatory cells are sources of growth factors and pro-angiogenic MMPs, and
therefore facilitate angiogenic responses.
With respect to cancer, the chick CAM has been used as an in vivo model to
evaluate angiogenesis (Chim, Qin et al. 2011), primary tumour growth (Gao, Cao et al.
2004), metastasis (Subauste, Kupriyanova et al. 2009), and to screen potential drugs
(Shen, Wang et al. 2010). There are several advantages of using the chick CAM model
system. For example, until day 11 or 12 o f embryonic development when the CAM has
expanded to fully envelope the embryo, the CAM vasculature is undergoing maturation
through the constant generation of new blood vessels (Deryugina and Quigley 2008).
Immediately prior to this time between days 8 and 10, the central portion o f the CAM is
developed and is very responsive to proangiogenic or antiangiogenic stimuli. Therefore,
the CAM is used as a model to test pro- or antiangiogenic compounds (Deryugina and
Quigley 2008). Additionally, the lymphoid system of the CAM is not fully formed until
the late stages of incubation, and is therefore relatively immunotolerant early in
development (Deryugina and Quigley 2008). As a result, the CAM can accept most cell
grafts without species-specific limitations, such as human tumour cells. Another benefit
o f the chick CAM is that growth of tumour xenografts on the surface o f the chick CAM is
very rapid (Figure 1.3), which is evidenced by the fact that visible tumours grow as early
as 4-7 days after tumour cell inoculation. In fact, some tumour cell types under ideal
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Figure 1.3

Rapid growth of tumour xenografts in the chick CAM model system

(A) The highly vascularized chick CAM consists o f three main layers. Epithelial ovarian
cancer cells can be xenografted onto the surface o f the chick CAM, and (B) are
inoculated at sites where large blood vessels at the surface intersect. Inoculating cells at
these sites will increase the probability o f successful tumour formation. (C) After 7 days,
1 x 106 MOSERM cells that had been seeded onto the CAM formed a tumour between 1
and 2 mm in diameter. Scale bars: 2 mm.
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seeding density conditions can form tumours as large as 500-600 mg within 7 days after
inoculation (Ossowski and Reich 1980). As well, not only can large tumours be seen at
the primary site of inoculation, but micrometastases can also be formed by invasion of
primary tumour cells into the stroma and intravasation into blood vessels during this time
period (Deryugina and Quigley 2008). As a result, multiple steps o f human cancer
progression can be recapitulated in the chick CAM model system in a very short period
of time relative to other in vivo model systems. Additionally, the CAM is a very simple
and inexpensive system relative to other models, making it ideal for large-scale
screenings and experiments (Staton, Reed et al. 2009). In addition to inoculations on the
surface o f the CAM, test compounds or drugs can be injected intravenously or intraallantoically. This is beneficial due to the fact that limited excretions out of the CAM
allows for the maintenance o f compounds in the circulation for extended periods of time.
Similarly, the easy accessibility and simplicity of the system also allows for repeated
treatments over time to the CAM if required.
However, there are some limitations of using the CAM system, particularly with
respect to angiogenesis. First of all, the CAM itself is well vascularized. Therefore can be
difficult to distinguish new capillaries from pre-existing capillaries (Staton, Reed et al.
2009). As well, irritation of the CAM during inoculations or injections can cause
inflammatory responses which can induce angiogenesis on its own (Deryugina and
Quigley 2008). The chick CAM has long been used as a common model system in
developmental biology, but has not been as common in the field o f cancer research which
has largely focused on mouse models in large part due to the ability to genetically
engineer these models (Hagedom, Javerzat et al. 2005). However, relatively new studies
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have highlighted techniques that may allow for genetic manipulation of the avian embryo
(Pekarik, Bourikas et al. 2003).
There are two ways in which the chick CAM can be prepared in order to perform
various assays, which are called the ‘in ovo’ and ‘ex ovo' methods. In the in ovo method,
fertilized eggs are placed in a humidified chamber at 37°C and the embryos are allowed
to partially develop (Ribatti, Vacca et al. 1996). Then, a small window can be cut in the
eggshell so that the underlying CAM is exposed and accessible. After this, the window is
often covered with cellophane tape until the desired assay is performed. In the ex ovo
method, the embryo and extraembryonic membranes are transferred to a Petri dish in the
early stages o f development, typically on day 3 or 4 o f development (Auerbach, Kubai et
al. 1974). The dish is then incubated at 37°C in a humidified chamber until the desired
assay is performed. Therefore, the CAM develops in the Petri dish as a flat membrane,
and reaches the edges o f the dish as it develops (Ribatti, Vacca et al. 1996). While both
techniques are considered to be minimally invasive, they both have advantages and
disadvantages associated with them. It is argued that the in ovo method requires less
maintainence during development (Staton, Reed et al. 2009). Additionally, embryos can
be maintained to later stages of development using this method. Due to the fact that the
entire CAM can be seen with the ex ovo method as opposed to only being able to see a
small portion of the CAM, multiple xenografts can be placed onto the surface o f each
CAM (Ribatti, Vacca et al. 1996). Although, there can be loss of embryos within the first
3 days following their transfer to Petri dishes, survival rates after this point are very good
and are comparable to the in ovo method (Auerbach, Kubai et al. 1974).
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The chick CAM has been used to study many types of cancer such as colon
cancer (Kim, Hur et al. 2011), gliomas (Auf, Jabouille et al. 2010), and pancreatic cancer
(Laklai, Laval et al. 2009). There have also been some studies that have investigated
aspects of ovarian cancer using the chick CAM system. For example, Kaempferol is a
naturally occurring flavonoid that is found in many fruits and vegetables (Luo, Rankin et
al. 2009). It was shown that when OVCAR3 human ovarian cancer cells were treated
with Kaempferol, tumour growth o f these cells was decreased as measured by tumour
weight. Additionally, angiogenesis was decreased in these treated cells as measured using
an angiogenesis onplant assay. A very similar study was done which tested the effect of
Apigenin on angiogenesis by placing Matrigel onplants containing Apigenin with
OVCAR3 cells onto the CAM (Fang, Zhou et al. 2007). Apigenin, which is also a
naturally occurring flavonoid, showed anti-angiogenic properties as measured by the
number o f new blood vessels formed. Studies have shown that soluble LI adhesion
molecule (sL l) protein is expressed at high levels in primary EOC tumour samples
(Fogel, Gutwein et al. 2003), and this protein has also been detected at high levels in the
ascites fluid o f ovarian cancer patients (Gutwein, Stoeck et al. 2005). The effects of sLl
on angiogenesis were then assessed by using the chick CAM angiogenesis onplant assay,
and it was shown that sLl significantly increases angiogenesis on the CAM based on
blood vessel density (Friedli, Fischer et al. 2009). Another study used malignant ascites
fluid (MAF) that was isolated from ovarian cancer patients using paracentesis
(Richardson, Gunawan et al. 2002). Although the MAF contained VEGF, it also
contained angiostatin and other anti-angiogenic factors. It was found that application of
MAF to the surface o f the chick CAM inhibited capillary formation. Other studies have
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been used to test the effectiveness of newly synthesized compounds on angiogenesis on
the chick CAM before being applied to other model systems. For example, a library of
compounds that were designed to be angiogenic inhibitors were applied directly to the
surface of the chick CAM, and two compounds were identified to significantly inhibit
angiogenesis as measured by blood vessel density (Dings, Chen et al. 2006). These two
compounds were then applied to an in vivo model in which M A I48 human ovarian
carcinoma cells were injected into athymic nude mice with or without daily
administration of the compounds. It was found that both compounds reduced tumour
growth as measured by tumour volume and weight, and these treated tumours were
confirmed to have decreased microvessel density. The authors o f the study then
suggested that their next steps would be to complete ongoing toxicity profiles in mice
followed by initiating phase I clinical trials in humans. Overall, the chick CAM can be
used as an effective model system to study multiple aspects o f tumourigenesis in various
types o f cancer. These studies that have been described that use the chick CAM to study
EOC provide evidence that this system can be effectively utilized for additional EOC
experiments. Therefore, my studies will involve using this model system in order to
further support its use as an effective tool to study EOC.

1.4

Objectives and experimental rationale
Based on previous data showing that upregulated BMP signaling decreased the

ability of EOC tumour cells to metastasize to form secondary nodules upon injection into
mice (Shepherd, Mujoomdar et al. 2010), I hypothesize that upregulated BMP signaling
in the mouse EOC cell lines will decrease EOC tumour formation on the chick CAM by
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decreasing the rate o f proliferation, and by inhibiting the angiogenic potential of these
cells. This hypothesis will be addressed by completing the following objectives:
A. Characterize proliferation, tumour formation, angiogenesis, and BMP signaling gene
expression in MOSERM, MASC2, and 4306 mouse EOC cell lines in vitro and on the
chick CAM
B. Assess role o f altered BMP signaling on EOC tumourigenesis and angiogenesis
C. Assess applicability o f the chick CAM as an alternative model system that can be used
to study multiple aspects o f EOC progression, specifically tumour formation and
angiogenesis
One of the important aims of my research is to support the use of the chick CAM
as an alternative model system that can be used to study multiple aspects of EOC
metastasis. The MOSERM, MASC2, and 4306 mouse EOC cell lines have not been well
characterized in the literature. Therefore, given that each of these cell lines formed in
mice, I will determine whether these cells will also be able to form tumours in another
model system by seeding them onto the chick CAM. I will then further characterize these
three mouse EOC cell lines by investigating what mechanism(s) are responsible for the
differences in tumourigenic potential that may be seen between the cell lines on the chick
CAM.
BMP signaling has been implicated in multiple aspects of EOC tumourigenesis
including EMT transition, cell adhesion, motility, and invasive potential in vitro
(Shepherd and Nachtigal 2003; Moll, Millet et al. 2006; Theriault, Shepherd et al. 2007).
It has also been implicated in limiting the ability of EOC cells to form secondary tumour
nodules in vivo (Shepherd, Mujoomdar et al. 2010). Therefore, I will further characterize
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the MOSERM, MASC2, and 4306 cell lines by assessing their relative expression levels
o f 84 TGFp/BMP signaling-related genes compared to normal mouse EOC cells.
Additionally, I will compare the relative BMP signaling expression levels of the mouse
EOC cell lines with one another in order to determine if there are any expression patterns
that will correlate with other tumourigenic properties that will be assessed.
Essential to gaining a better understanding of the complex roles that BMP
signaling plays in EOC is to alter the expression and activity o f this pathway in
MOSERM, MASC2, and 4306 cells. One approach to accomplish this is to stablytransfect cells with ALK3QD, which is a constitutively-active type I BMP receptor. BMP
signaling will also be altered in parental mouse EOC cell lines by administering short
term treatment of BMP4, BMP antagonist noggin, or BMP receptor type I inhibitor LDN193189. These methods will allow me us to assess the role of altered BMP signaling on
tumour formation on the chick CAM, proliferation, cell survival, and angiogenesis using
multiple strategies.
Angiogenesis will be assessed in the ALK3QD clones as well as in the initial
characterization of angiogenic potential in the three parental mouse EOC cell lines by
using an innovative chick CAM angiogenesis onplant assay. I will therefore have the
opportunity to further develop the chick CAM as a model system that can be used to
study EOC by utilizing it in these angiogenesis studies as well as in tumour formation
studies.
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CHAPTER TWO

MATERIALS AND METHODS

2.1

Cell lines
The MOSERM cell line (gift from Dr. Barbara Vanderhyden, University of

Ottawa, Ottawa, ON) was derived from mouse ovarian surface epithelial cells isolated
from transgenic mice expressing a temperature sensitive mutant of SV40 large T antigen
(Yao, Li et al. 2006). These cells were subsequently transfected with plasmids to
ectopically express the Ras and Myc oncogenes. The MASC2 ovarian cancer cell line
(gift from Dr. Barbara Vanderhyden, University o f Ottawa, Ottawa, ON) was derived
from the ascites fluid o f mice with metastatic ovarian tumours due to the conditional
transgenic expression of SV40 large T antigen specifically in the OSE (Laviolette,
Garson et al. 2010). The 4306 ovarian cancer cell line (gift from Dr. Daniela Dinulescu,
Brigham and Women’s Hospital, Boston, MA) was derived from the ascites fluid of
conditional transgenic mice with metastatic ovarian cancer. These mice express
oncogenic mutant KrasGl2D in addition to having an inactivated Pten tumour suppressor
gene specifically in the OSE (Dinulescu, Ince et al. 2005).

2.2

Cell culture
The MOSERM and MASC2 murine ovarian cancer cell lines were grown in

Alpha Modification of Eagles’ Medium (AMEM - Wisent, St. Bruno, QC, Canada)
supplemented with 5% Fetal Bovine Serum (FBS - Wisent). The 4306 murine ovarian
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cancer cell line was grown in Dulbecco’s Modified Eagle’s Medium (DMEM - Wisent)
supplemented with 5% FBS. MOSERM, MASC2, and 4306 cells were grown in standard
tissue culture-treated polystyrene plates (Sarstedt, Montreal, QC). Primary HUVECs (gift
from Dr. John Lewis, London Regional Cancer Program, London, ON) were grown in
Endothelial Cell Complete Growth Medium (EGM - Lonza, Walkersville, MD)
containing 2% FBS and supplemented with 0.4% Bovine Brain Extract (BBE - Lonza).
HUVECs were grown and maintained in Cell+ T175 flasks (Sarstedt). Cells were
detached from tissue culture plates for passaging with 0.25% Trypsin/1%EDTA solution
(Wisent), which would then be deactivated with media containing 5% FBS. Cells were
maintained in humidified chambers at 37°C with 95% air and 5% CO 2 .

2.3

Establishment of GFP and GFP-ALK3QD clones
MOSERM, MASC2, and 4306 GFP clones were previously created (work

completed by Yudith Ramos-Valdes) using a murine stem cell virus (MSCV) retroviral
vector. HEK293T cells were used as a packaging cell line, which were transfected using
SuperFect® Transfection Reagent (Qiagen, Toronto, ON). At day 1, the SuperFect®
Transfection Reagent was added to DMEM along with a MSCV Puro IRES GFP viral
vector (MSCV PIG) containing GFP and the Puromycin resistance gene, v|/ packaging
vector, and vesicular stomatitis virus glycoprotein (VSVG) plasmid. After 24 hours,
media on the transfected plates was changed. At day 5, approximately lOOpL of virus
containing media from the HEK293T transfected plates was added to 6cm plates with the
cell lines o f interest that were to be infected (MOSERM, MASC2, 4306). After 24 hours,
media on these infected plates was changed. Finally, these cells were placed under
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Puromycin (BioShop, Burlington, ON) selection pressure at a concentration of lpg/mL
after which time 5 GFP-expressing clones from each of the parental cell lines
(MOSERM, MASC2, 4306) were isolated and expanded (worked completed by Yudith
Ramos-Valdes).
ALK3QD clones were created by transfecting MOSERM-GFP, MASC2-GFP,
and 4306-GFP cells with a pcDNA 3.0 expression vector (Invitrogen, Carlsbad, CA)
containing hemagglutinin (HA) -tagged hALK3QD. The ALK3QD (Q233D) BMP type I
receptor contains a Q-to-D point mutation in its glycine/serine rich domain at amino acid
233 (Hoodless, Haerry et al. 1996). As a result, this removes the requirement of
transphosphorylation by BMPRII due to BMP ligand binding for the BMP type I receptor
to be activated. GeneJuice® Transfection Reagent (Novagen, Mississauga, ON) was used
in these transfections. Briefly, 15 pL GeneJuice® was added to 300pL of either AMEM
(MOSERM GFP and MASC2 GFP cells) or DMEM (4306 cells) followed by the
addition o f 5 pg HA-tagged hALK3QD pcDNA 3.0 (0.45 pg/pL). This mixture was
added to 60mm plates that were going to be transfected, which were then incubated for
72 hours. After this time, cells were placed under G418 (Wisent) selection pressure at
concentrations o f 800 pg/mL for 10-14 days. After this time, 4 MOSERM, 2 MASC2,
and 5 4306 GFP ALK3QD clones were isolated and expanded.

2.4

In vitro cell proliferation and survival assays

Cell proliferation was assessed either by cell counting using a haemocytometer, or
by alamarBlue® (Invitrogen) proliferation assays. For cell counting, 5000 cells of each
cell line were seeded onto 60 mm plates in 5 mL media, and were grown for up to 5 days.
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Each day, adherent cells were exposed to trypsin for all approximately 5 minutes, and
following cell detachment, the trypsin was inactivated using FBS-containing media. To
evaluate total cell number, trypsinized cells were counted using a haemocytometer by
averaging 2 haemocytometer counts for each plate.
For alamarBlue® proliferation, 500 cells were seeded into the wells of 96-well
plates, and were grown for up to 5 days in 200 pL of media. At each time point (days 0,
1, 2, 3, 4, 5) media was aspirated and replaced with 200 pL o f a 1:20 ratio of
alamarBlue®: media. The alamarBlue® treated 96-well plates were then incubated at 37°C
for 4 hours. At this time, the reactions were measured fluorometrically using a Wallac
1420 Multilabel Counter (Perkin Elmer Wallac, Gaithersburg, MD) with a fluorescence
protocol. This protocol uses a fluorescence excitation wavelength of 570 nm, and
fluorescence emission at 585 nm in order to quantify fluorescence units.
Cell survival was measured using similar conditions as the alamarBlue

(K)

proliferation assay, but with some modifications. For the MOSERM and MASC2 cell
lines, 5000 cells were seeded into the wells o f a 96-well plate. For the 4306 cell line,
10000 cells were seeded into the wells o f a 96-well plate. The cells were then grown for
up to 5 days in 200 pL o f serum-free media (0% FBS). At each time point (days 0, 1,2,
3, 4, 5), media was aspirated and replaced with 200 pL of a 1:20 ratio o f alamarBlue®:
serum-free media. Cell survival was then measured as described above using the Wallac
1420 Multilabel Counter. Seeding densities are based on a preliminary 5 day serumstarving alamarBlue® experiment in which various quantities o f cells (2000-10000 cells
in 96-well plates) for each line were seeded in order to determine the minimum amount
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o f cells that had to be seeded in order to be able to achieve a quantifiable fluorescence
signal after 5 days.

2.5

RNA isolation and gene expression profiling
RNA isolation from cells grown in monolayer was completed by using an RNeasy

Mini Kit (Qiagen) as per manufacturer’s instructions. The isolated RNA was then treated
using an Amplification Grade DNase I kit (Sigma-Aldrich, Oakville, ON) in order to
remove contaminating DNA as per manufacturer’s instructions. The quality and quantity
o f the isolated RNA was determined using a Nano Drop 1000 Spectrophotometer
(NanoDrop Products, Wilmington, DE).
Gene expression profiles for the MOSERM, MASC2, and 4306 cell lines were
assessed by using a TGFJ3/BMP Signaling Pathway RT2 Profiler PCR Array System
(SABiosciences # PAMM-035, Frederick, MD). This array uses 96-well plates that
contain optimized primers in each well for genes of interest that are involved in the
TGFp/BMP signaling pathway. The array also contains wells for several housekeeping
genes, as well as control wells for PCR performance, RNA quality, and genomic DNA
contamination. Briefly, 1 pg DNase-treated RNA was used for first strand cDNA
synthesis that was completed using an RT2 First Strand Kit (SABiosciences) as per
manufacturer’s instructions. This newly-synthesized cDNA in a volume of 102pL was
mixed with RT2 SYBR® Green/Rox1MqPCR Master Mix (SABiosciences) as per
manufacturer’s instructions that contained all of the buffers and reagents that are required
for real-time PCR (real-time PCR buffer, nucleotides, high-performance HotStart DNA
Taq polymerase, ROX® reference dye). Then, 25 pL o f the master mix/cDNA mixture

54
was aliquoted in each o f the wells o f the 96 well-plates, and plates were run using a
Strategene Mx3000P QPCR machine (Agilent Technologies, Cedar Creek, TX). Data
analysis of the results was quantified using a PCR Array Data Analysis Web Portal for
Excel (SABiosciences).

2.6

Western blotting
Total cellular protein was isolated by first scraping cells from their cell culture

plates, and then washing them with cold Dulbecco’s Phosphate-Buffered Saline (PBS)
(Wisent). These cells were pelleted by centrifugation (5 minutes at 2000 x g), and were
then dissolved in lysis buffer (50mM HEPES pH 7.4, 150mM NaCl, 10% glycerol,
1.5mM MgCb, ImM EGTA, 10 mM sodium pyrophosphate, ImM sodium
orthovanadate, lOmM NaF, ImM PMSF, 0.1% SDS, 1% sodium deoxycholate, 1%
Triton X-100, and IX protease inhibitor cocktail (Roche, Mississauga, ON)) for 20
minutes, at which time total cellular protein was clarified by centrifugation (20 minutes at
14000 xg).
The protein concentration of each lysate was determined by Bradford analysis as
described previously (Bradford 1976), with some modifications. Briefly, a standard curve
was generated using increasing concentrations of Bovine Serum Albumin (BSA) (New
England Biolabs, Pickering, ON) by using Protein Assay Dye Reagent Concentrate (BioRad Laboratories, Mississauga, ON). The colourimetric assay was quantified using a
Model 3550 Microplate Reader (Bio-Rad Laboratories). Protein samples were then
diluted by between 1:100 and 1:1000 in PBS, and 200pL of diluted protein was added to
wells in a 96-well plate. lOOpL of Protein Assay Dye Reagent that was diluted 2:1 with
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PBS was added to each well, and values were quantified using the Model 3550
Microplate Reader. Finally, protein concentration was determined based on interpolation
using the standard curve.
Protein extracts (50-90 pg) were resolved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) using 8% or 12% gels. These proteins
were transferred to a polyvinylidene difluoride membrane (PVDF - Roche), and were
subsequently blocked with 5% skim milk in Tris-buffered saline and Tween 20 (TBST lOmM Tris-HCl pH 8.0, 150mM NaCl, 0.1% Tween 20) for at least one hour at room
temperature. Membranes were washed in TBST and incubated overnight at 4°C in TBST
in 5% skim milk with 0.02% NaN 3 and appropriate concentrations of primary antibodies
(actin, ID1, ID3, phospho-Smad 1/5/8, Sm adl, HA high affinity - 1/1000). After this, the
membranes were incubated in anti-rabbit horseradish peroxidase (HRP)-linked secondary
antibody (1/10,000 - GE Healthcare, Piscataway, NJ) for one hour at room temperature.
Membranes incubated with anti-HA high affinity primary antibody were incubated in
goat anti-rat HRP-linked secondary antibody (1/25,000 - Thermo Fisher Scientific,
Toronto, ON). Immunoreactive bands were visualized by incubating the membranes for
five minutes with chemiluminescence detection reagent (ECL Plus - GE Healthcare),
exposing them to Hyperfilm™ ECL high performance chemiluminescence film (GE
Healthcare), and developing them using a Kodak M35A X-OMAT Processor (Kodak
Graphic Communications Company, Toronto, ON).
In some instances, blots were stripped to reprobe with different primary
antibodies. Briefly, membranes were incubated with stripping buffer (2% SDS, lOOmM
P-mercaptoethanol, 62.5mM Tris-HCl pH 6.8) for approximately 45 minutes at 70°C.
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The membranes were washed several times in TBST for at least 40 minutes. After this,
membranes were reprobed beginning with blocking the membranes with 5% skim milk in
TBST for at least one hour at room temperature as described above.

2.7

Antibodies and other reagents
Antibodies against total Smadl (# 9517) and phospho-Smad 1/5/8 (# 9511) were

purchased from Cell Signaling Technologies (Danvers, MA). The antibodies against ID1
(# BCH-1/195-14) and ID3 (# BCH-4/6-1) were purchased from BioCheck Inc. (Foster
City, CA). Anti-actin antibody (# A2066) was purchased from Sigma-Aldrich. Anti-HA
high affinity antibody (# 11 867 423 001) was purchased from Roche. LDN-193189 BMP
type I receptor inhibitor was purchased from Axon Medchem BV (Groningen, The
Netherlands). Recombinant human Noggin and BMP4 were both purchased from R&D
Systems #6057-NG-025 and 314-BP-010, Burlington, ON). LDN-193189, Noggin, and
BMP4 were reconstituted as per product specifications.

2.8

Chick CAM tumour imaging and growth assay
Tumour growth assays on the chick CAM were performed similarly to other

studies (Mitchell, Pobre et al. 2010). Fertilized White Longhorn chicken eggs were
purchased from McKinley’s Hatchery (St. Mary’s, Ontario), and incubated in a rotary
incubator at 38°C and 80% humidity. At day 4 of development, eggshells were removed
and the embryos were carefully placed into weigh boats. Embryos were covered with lids
and placed in a humidified stationary air incubator at 38°C and 80% humidity. At day 10
o f development, the CAM was gently abraded with sterile filter paper that was
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approximately 7 mm in diameter. After 10 minutes, the filter paper was gently removed
using jew eler’s forceps, and 25uL of cells (1,000,000 cells per 25uL PBS) were
inoculated onto the surface o f the CAM at the abraded site. Inoculation sites were chosen
where large blood vessels intersected on the surface o f the CAM, and that were also
approximately an equal distance between the embryo and the edge of the weigh boat. The
embryos were returned to the humidified stationary air incubator for the remainder of the
experiment. After 7 days o f incubation (i.e. at day 17 of development), images of tumour
nodules were captured using PS Remote (Breeze Systems Ltd, Camberly, UK) and Paint
Shop Pro 9 (Jasc Software, Ottawa, ON) with a StereoLumar.V12 fluorescence dissection
microscope (Carl Zeiss, Toronto, ON) mated to a Hamamatsu ORCA-ER camera (Digital
Imaging Systems Ltd, Buckinghamshire, UK). After imaging, tumours were excised and
placed in Formalde-Fresh Solution (Thermo Fisher Scientific) overnight, and were then
weighed using a Mettler AE240 digital semi-micro analytical balance (Mettler-Toledo
Inc, Columbus, OH).

2.9

In Vitro angiogenesis assay

In vitro angiogenesis assays were performed as described previously (Kubota,
Kleinman et al. 1988), with some modifications. Matrigel1M Basement Membrane Matrix
(BD Biosciences, Mississauga, ON) which is a solubilized basement membrane extracted
from Engel-Holm-Swarm (EHS) sarcomas, was diluted 1:2 with chilled EGM. This
diluted Matrigel (60pL) was added to wells of a 96-well culture plate, and incubated at
37°C for 1-2 hours to allow for polymerization. HUVECs were plated onto the layer of
gelled Matrigel at a concentration of 10,000 cells/50pL EGM, and were co-cultured with
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50pL of mouse epithelial ovarian cancer cells (5000 cells/50pL media) in serum-free
media. The plates were incubated at 37°C in 5% CC>2/95% air. After 3-6 hours, each well
was photographed with an Olympus 1X70 inverted microscope using Image-Pro Plus 6.2
(Media Cybernetics Inc., Bethesda, MD). Endothelial tube formation was quantified in
each well by counting the number of branch points in 6-12 random fields of view at 100X
magnification.

2.10

Chick CAM angiogenesis assay
Angiogenesis assays were performed as described previously (Seandel, Noack-

Kunnmann et al. 2001), with some modifications. Briefly, high concentration rat-tail type
I collagen (BD Biosciences) in autoclaved H2 O was neutralized with 10X PBS and 0.1N
NaOH at a ratio of 8:1:1. The volumes o f rat-tail type I collagen/autoclaved water varied
to attain a final concentration o f neutralized collagen at 2.5 mg/mL. Hepes solution
(Sigma Aldrich) was added at a final concentration of 20mM to ensure a stable pH of 7.4.
The pH of the final neutralized collagen solution was tested and additional 0.1 N NaOH
was added if necessary. Two parts o f neutralized collagen solution were combined with
one part sterile IX PBS containing BSA (final concentration 1 mg/mL) as a carrier
protein. Finally, cells of interest were incorporated into the collagen at a concentration of
4 x 107 cells per mL.
Thirty microlitres o f the final collagen/cell solution were pipetted onto 2 layers of
sterile nylon mesh grids (Innovascreen, Halifax, NS). The mesh, which was cut and
autoclaved beforehand, was prepared by placing the upper mesh (2mm x 2mm) onto the
lower mesh (3mm x 3mm) at a 45° angle. For each experimental group, 40 collagen/mesh
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onplants were laid onto Parafilm (Pechiney Plastic Packaging Company, Cleveland, OH)
in 100 x 100 mm Petri dishes, and placed at 37°C for 3 hrs to allow for collagen
polymerization into fibrils. Jeweler’s forceps were used to place four onplants onto each
CAM o f 9-day-old chick embryos. The onplant-bearing embryos were incubated for an
additional 3 days, at which time onplant vascularization was quantified. Newly formed
vessels were identified by analyzing the upper plane of the onplant with a dissecting
microscope. The angiogenic index o f the onplants was determined as the percentage of
mesh grids that contained newly formed blood vessels out of the total number of grids in
the upper mesh. Images were captured using Volocity (Improvision Inc., UK) with a
StereoLumar.V12 fluorescence dissection microscope mated to a Hamamatsu ORCA-ER
camera.

2.11

Statistical Analyses
Data are expressed in figures as the mean ± standard error of the mean (SEM).

When comparing an experimental sample with its matched control, a two-tailed unpaired
Student’s t-test was used. To compare the means among more than two samples, a one
way analysis of variance was used followed by Tukey’s post hoc analysis. Differences
with p values < 0.05 are considered to be statistically significant. These statistical
analyses were performed using GraphPad Prism version 3.0 software (GraphPad
Software Inc, San Diego, CA).
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CHAPTER THREE

RESULTS

3.1

MOSERM and 4306 mouse ovarian cancer cell lines form tumours on the
chick chorioallantoic membrane (CAM)
The MOSERM, MASC2, and 4306 mouse ovarian cancer cell lines have not been

well characterized either in vitro or in vivo in the literature. Given that each of these cell
lines are able to form tumours in mice, I sought to determine the tumourigenic potential
of each cell line in another model system by seeding them onto the chick CAM. The
GFP-expressing clones that our lab has previously developed (work by Yudith RamosValdes) were used for this experiment so that cells could be visualized by fluorescence
microscopy even if macroscopic tumours were not formed, and to confirm that nodules
that were formed were indeed composed o f ovarian cancer cells. For each cell line, 1 x
106 cells in 25pL were seeded onto the surface o f the CAM. After one week, tumour
formation was assessed. MOSERM and 4306 cells form macroscopic tumour nodules on
the chick CAM that and are consistently larger than 1 mm in diameter (Figure 3.1 A). In
fact, MOSERM tumours are visibly larger than the 4306 tumours. Since MASC2-GFP
cells that were seeded onto the CAM did not form visible tumour nodules, fluorescence
images were taken every day after the initial seeding to determine if these cells were
present and able to survive on the CAM (data not shown). Although these cells were
visible under fluorescence on the CAM up to approximately four days after seeding, they
were no longer detectable on the CAM by day 7.
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Figure 3.1

MOSERM and 4306 cells form tumours on the chick CAM.

Approximately 1 x 106 cells were seeded onto the surface of each chick CAM at
embryonic day 11. (A) Brightfield and fluorescent images of the xenograft locations were
taken 7 days after the initial seeding at 20X magnification. (B) The tumours were then
excised from the surface of the CAM, placed in formalin overnight, and weighed. Error
bars represent the standard error o f the mean for tumour weight from at least 6 excised
tumours per group. Asterisks indicate statistically significant differences between
treatments (**p = 0.0087). Scale bars: 2 mm.
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In order to quantify differences in the size of the tumours formed on the chick
CAM between MOSERM and 4306 cells, the tumours were excised and weighed.
MOSERM cells consistently formed tumours with an average weight o f 9.1 ± 1,9mg that
were significantly larger than tumours formed from 4306 cells (p = 0.0019), which had an
average weight of 3.3 ± 0.4mg (Figure 3 .IB).

3.2

Tumour forming ability on chick CAM does not correlate with in vitro
proliferation
To evaluate whether differences in the rate of proliferation between each cell line

were correlated with their abilities to form tumours on the chick CAM, in vitro
proliferation studies were completed over five days. Among the three mouse ovarian
cancer cell lines, MOSERM cells exhibited the highest rate o f proliferation. These cells
grew from an initial seeding density of 5000 cells to 11.5 x 106 cells within the 5 day
period o f this assay (Figure 3.2A), and had a peak doubling time o f 9.8 hours (Figure
3.2B). MOSERM cells grew significantly more rapidly than both the MASC2 and 4306
cell lines (p < 0.001). Interestingly, MASC2 cells proliferate with a peak doubling time of
11.4 hours, which represented growth from 5000 to 3.5 x 106 cells within 5 days. This
level o f proliferation for MASC2 cells is significantly greater than 4306 cells (p < 0.05),
which have a peak doubling time o f 12.8 hours that represents growth from 5000 to 1.5 x
106 cells in 5 days.
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Figure 3.2

Differences in the rate of proliferation of mouse EOC cell lines grown

in vitro.

For each cell line, 5000 cells were seeded onto 60 mm plates and were grown for up to 5
days. At each time point, cells were trypsinized and counted. (A) Values represent the
average number o f cells between 3 replicates, and 2 haemocytometer counts were
performed for each replicate. Bars represent the standard error o f the mean for each group
at each time point. (B) The peak doubling time for each cell line was calculated in hours
by using the formula To = l/[ln(Nt/N0)/t](ln2) where Nt is the number o f cells after the
desired time interval (5 days) in the exponential growth phase, N0 is the number of
starting cells, and t is the length o f the experiment in hours (Mehrara, Forssell-Aronsson
et al. 2007).
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3.3

In vitro angiogenesis correlates with mouse EOC cell line tumour-forming

ability on the chick CAM
Since the rate o f proliferation o f each cell line does not correlate with their
relative abilities to form tumours on the chick CAM, we sought to investigate
angiogenesis as a potential mechanism to define these tumour formation differences
among cell lines. To accomplish this, HUVECs were co-cultured with each cell line in
low serum-containing media (1% FBS) on a layer a Matrigel in 96-well plates. After 6
hours, multiple images of each well at 100X magnification were taken, and representative
images of wells with HUVEC branching in the presence o f AMEM treatment (Figure
3.3A) or MOSERM cells (Figure 3.3B) are shown. MOSERM cells significantly
enhanced the ability o f HUVECs to form branches (16.6 ± 0.5 branches per field of view)
relative to AMEM alone (12.4 ± 0.3 branches per field of view; p = 0.0016; Figure 3.3C).
Co-culture o f HUVECs with 4306 cells also significantly enhanced HUVEC branching
(10.7 ± 0.2 branches per field o f view) compared to DMEM alone (8.0 ± 1.0 branches per
field of view; p - 0.0191). In contrast, treatment o f HUVECs with MASC2 cells did not
significantly affect the rate o f branching (8.1 ± 1.0 branches per field o f view) when
compared to AMEM alone (7.8 ± 0.7 branches per field of view).

3.4

In vivo angiogenic potential of mouse EOC cells assessed using the chick

CAM
The chick CAM has been previously been used as an in vivo model system to
assess angiogenesis. In order to determine if the abilities of MOSERM and 4306 cell
lines to induce angiogenesis in vitro can also be detected in vivo, chick CAM
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Figure 3.3

Angiogenesis as a potential mechanism defining differences in mouse

EOC tumour formation on the chick CAM.
1 x 104 human umbilical vein endothelial cells (HUVECs) were plated onto Matrigel and
co-incubated with 5000 MOSERM cells, MASC2 cells, or 4306 cells in low serumcontaining media (1% FBS) in 96 well plates. After 3-6 hours, angiogenesis was
quantified. Angiogenesis is measured by counting the number o f branches formed by
HUVECs per field o f view. Representative images of branches within a field of view in a
96-well plate at 100X magnification are shown for AMEM control (A) and MOSERM
cells (B). HUVEC branches are indicated by black arrows. The image for AMEM
treatment contains 13 branches, while the image for MOSERM treatment contains 16
branches. (C) Branch counts for each cell line are represented by grey bars, while branch
counts for their respective serum-free media treatments are represented by black bars.
Error bars represent standard error of the mean for the average number of branches based
on at least 4 wells per group. Pairwise comparisons were made within each pair of
treatments, and asterisks indicate statistically significant differences within each pair (*p
= 0.0191, **p = 0.0016).
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angiogenesis assays were performed as described previously (Seandel, Noack-Kunnmann
et al. 2001). Angiogenesis was quantified by expressing the number of grids that are
positive for blood vessel sprouting as a percentage o f total grids in each mesh.
Representative images o f blood vessel sprouting are shown for PBS control (Figure 3.4A)
and MOSERM cell (Figure 3.4B) groups. Quantification of the PBS control group
indicated a baseline level of new blood vessel sprouting over the 3-day period of the
experiment, which was approximately 7.8 ± 0.5% o f the total grid area (Figure 3.4C).
Collagen onplants containing MASC2 cells induced angiogenesis in an average of 11.4 ±
1.7% of grid boxes. However, this difference in blood vessel sprouting is not statistically
significant between the PBS and MASC2 groups. MOSERM collagen onplants showed
angiogenic sprouting in 18.3 ± 2.5% o f grid boxes, and 4306 onplants exhibited sprouting
in 20.9 ± 1.3% of grid boxes. These enhanced levels o f blood vessel sprouting are
significantly greater in both the MOSERM (p < 0.05) and 4306 (p < 0.01) onplants
relative to the PBS treatment group, as well as when compared to the MASC2 treatment
group (p < 0.05). There was no significant difference in the degree of sprouting between
the MOSERM and 4306 treatment groups.
3.5

Inverse correlation of mouse EOC cell line BMP4 signaling gene expression
and tumour formation on the chick CAM
BMP signaling has been implicated in the progression of ovarian cancer in

numerous studies (Shepherd and Nachtigal 2003; Moll, Millet et al. 2006; Theriault,
Shepherd et al. 2007; Shepherd, Theriault et al. 2008; Pils, Wittinger et al. 2010;
Shepherd, Mujoomdar et al. 2010). Previously, 4306 cells have been shown to possess an
intact Mullerian Inhibiting Substance (MIS) signal transduction pathway based on ALK2,
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Figure 3.4

Differences in angiogenic potential between mouse EOC cell lines are

revealed on the chick CAM.
1 x 105 MOSERM, MASC2, or 4306 cells were embedded in collagen, which was then
inserted between two mesh grids and placed on the surface of the chick CAM. After 3
days, angiogenesis was quantified. The degree o f new blood vessel sprouting was
measured by counting the number o f grid boxes within each mesh that were positive for
blood vessel sprouting. Representative images with blood vessel sprouting for PBS
control (A) and MOSERM cells (B) are shown. Examples o f grid boxes that are positive
for new blood vessel sprouting are indicated by black arrows. The PBS mesh grid
contains 3 of 47 boxes that are positive for blood vessel sprouting (6.4%), while the
MOSERM mesh grid contains 6 of 41 boxes that are positive for blood vessel sprouting
(17.1%). Note that a positive grid is determined if blood vessel sprouting is present,
regardless o f how many sprouts are within that grid box. (C) The percentage of grids that
were positive for angiogenic sprouting is represented for each treatment group. Error bars
represent standard error of the mean for the average percentage o f positive grids based on
at least 7 mesh grids per group. Different letters represent statistically significant
differences among groups (p < 0.05).
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ALK3, MISRII, and Smadl/5/8 mRNA expression (Szotek, Pieretti-Vanmarcke et al.
2006). However, other aspects o f TGFp/BMP signaling have never been assessed in these
cells, and TGFp/BMP signaling has never been evaluated in MOSERM or MASC2 cells.
Therefore, we sought to compare the BMP signaling expression profiles o f these mouse
ovarian cancer cell lines, and then investigated whether there were correlations between
the BMP expression levels and the relative abilities of these cell lines to form tumours on
the chick CAM or to induce angiogenesis. The gene expression profiles for the
MOSERM, MASC2, and 4306 cell lines were assessed using a TGFp/BMP Signaling
Pathway RT Profiler

PCR Array System. As well, the gene expression profile of

normal mouse OSE (isolated by Dr. Trevor Shepherd) was also assessed in order to
provide an additional comparison to the three mouse ovarian cancer cell lines. In addition
to the normal mouse OSE cells, the MOSERM, MASC2, and 4306 cell lines all have
measurable, but distinct mRNA expression levels for the components required for BMP4
signaling (BMP4 ligand, BMP receptors, receptor Smads, co-Smad4, BMP responsive
target genes; Figure 3.5). BMP4 mRNA is expressed in MOSERM cells at a level of 8.3
± 0.5% relative to the expression levels o f a panel of control genes, which was not
significantly different than BMP4 expression in 4306 cells of 5.1 ± 1.0%. In mouse OSE
cells, BMP4 is expressed at higher levels of 11.0 ± 0.2% when compared to 4306 (p <
0.01), but not to MOSERM cells. Interestingly, BMP4 is expressed at 19 ± 0.9% in
MASC2 cells, which is significantly higher than MOSERM, 4306, and OSE cells (p <
0.001). One of the last steps in the BMP4 signaling pathway is the upregulation of target
gene expression, such as the Ids. Idl mRNA is expressed in MOSERM cells at a level of
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Figure 3.5

Expression of BMP pathway signaling components among mouse

EOC cell lines and normal mouse OSE cells.
TGFp/BMP signaling was assessed using a SABiosciences RT2 Profiler1MPCR Array.
Expression of mRNA for each group represents the average of arrays that were
completed in duplicate, with error bars representing the standard error o f the mean. The
expression levels o f each gene of interest for MOSERM, MASC2, 4306 and normal
mouse OSE cells were normalized to the average expression level o f a panel o f five
housekeeping genes (glucuronidase-beta (Gusb), hypoxanthine guanine phosphoribosyl
transferase 1 (H prtl), heat shock protein 90kDa alpha cystolic-class B member 1
(Hsp90abl), glyceraldehyde-3-phosphate-dehydrogenase, actin-beta cytoplasmic (Actb)).
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9.5 ± 0.7%, at 11.1 ± 0.6% in 4306 cells, and 8.9 ± 0.8% in mouse OSE, with none of
these groups having significantly different expression levels from one another. However,
Idl in MASC2 cells is expressed at a level of 24.4 ± 0.1% relative to the expression
levels of housekeeping genes, and is expressed at significantly higher levels compared to
MOSERM, 4306, and OSE cells (p < 0.001). Similar to Idl, Id2 is not expressed at
statistically different levels between MOSERM and 4306 cells, which express Id2 mRNA
at levels o f 9.6 ± 2.1% and 12.2 ± 0.4%, respectively. However, MASC2 cells express
Id2 at a level o f 24.6 ± 0.1%, and mouse OSE cells express Id2 at 26.9 ± 0.5%. These
expression levels in MASC2 cells for Id2 are significantly greater than those for
MOSERM or 4306 cells (p < 0.001). Other components of the BMP4 signaling pathway
that were assessed (ALK3, BMPR2, Sm adl, Smad4, Smad5) did not have statistically
significant differences among cell lines or normal mouse OSE.

3.6

Ectopic stable expression of constitutively-active ALK3QD receptor in mouse
EOC cells
MOSERM-GFP, MASC2-GFP, and 4306-GFP cells were all stably transfected to

express the constitutively active type I BMP receptor, ALK3QD (Hoodless, Haerry et al.
1996). This ALK3QD is also HA-tagged so that successful transfections can be
visualized by western blot. We originally screened 38 MOSERM clones, 12 MASC2
clones, and 14 4306 clones. From these screens, two independent clones for each o f the
three cell lines were expanded that were positive for ALK3QD-HA expression (Figure
3.6). The majority of these clones (MOSERM ALK3QD clones 1 and 2, MASC2
ALK3QD clones 1 and 2, 4306 clone 1) exhibited a relatively low level of ALK3QD
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Figure 3.6

Changes in BMP signaling as a result of transfection of mouse EOC

cell lines with ALK3QD.
Transfected ALK3QD clones are divided into two groups based on their BMP signaling
expression levels compared to parental cells. (A) One group of transfected clones exhibits
increased downstream BMP signaling relative to parental cells, while the other group (B)
exhibits decreased BMP signaling compared to parental cells. (Top panel o f A and B)
Successful transfections of mouse EOC cell lines with HA-tagged ALK3QD was
assessed with anti-HA high affinity. Western blotting was performed by using 90pg of
total cellular protein, and equal loading was assessed with anti-actin. (Bottom panel of A
and B) The effect o f ALK3QD transfections on downstream BMP signaling was assessed
using anti-phospho-smad 1/5/8, anti-ID 1, and anti-ID3. Western blotting was performed
with 50pg o f total cellular protein, and equal loading was assessed with anti-Smadl and
anti-actin. BMP signaling was considered to be upregulated or downregulated based on a
change in phospho-Smad 1/5/8 protein expression, as well as a change in at least one of
either Idl or Id3 protein expression.
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expression as measured by western blot (top panel of Figure 3.6A and 3.6B), but 4306
clone 2 exhibited much stronger ALK3QD expression compared to the other clones.
Therefore, we were especially interested to investigate whether this strong signal would
have unique functional consequences. The six clones are divided into two groups based
on the effects o f ALK3QD expression on downstream BMP signaling. These groups are
differentiated based on whether downstream BMP signaling in the clones is upregulated
or downregulated relative to parental cells. BMP signaling was considered to be
upregulated or downregulated based on a change in phospho-Smad 1/5/8 protein
expression, as well as a change in at least one o f either Idl or Id3 protein expression.
Clones with increased BMP signaling relative to parental cells are denoted by a (+) sign,
while clones with decreased BMP signaling are denoted by a (-) sign.
The first group contains MOSERM ALK3QD clones 1 (+) and 2 (+), and 4306
ALK3QD clone 2 (+) (Figure 3.6A). One of the first steps in the BMP signaling pathway
is the phosphorylation of R-Smads, and we therefore assessed phospho-Smad 1/5/8
protein expression compared to total Smad levels. The MOSERM clones in the first
group exhibit an increase in phospho-Smad 1/5/8 expression relative to parental cells,
although these clones also exhibit an increase in total Smad 1/5 (bottom panel of Figure
3.6A). 4306 ALK3QD clone 2 (+) cells display a more pronounced increase in phosphoSmad 1/5/8 expression compared to 4306 parental cells, and do not have any noticeable
changes in total Smadl/5 levels. In addition to phospho-Smadl/5/8, Idl and Id3 target
gene protein expression were also assessed. Both of these proteins are expressed at higher
levels in ALK3QD (+) clones in this first group when compared to parental cells,
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although changes in Idl and Id3 protein expression are more pronounced in the
MOSERM ALK3QD (+) clones than in the 4306 ALK3QD (+) clone.
The second group o f clones includes MASC2 ALK3QD clones 1 (-) and 2 (-), and
4306 clone 1 (-) (Figure 3.6B). Both MASC2 ALK3QD clone 1 (-) and 4306 ALK3QD
clone 2 (-) display a decrease in phospho-Smad 1/5/8 expression compared to parental
cells, while MASC2 ALK3QD clone 2 (-) cells display a less apparent decrease in the
expression o f this protein (bottom panel Figure 6B). Additionally, total Smadl/5
expression does not change between any o f the clones and their respective parental cell
lines. With respect to the Id proteins, Idl expression decreases in all three clones relative
to parental cells. However, Id3 protein expression does not change among the clones and
their parental cells.

3.7

Inverse correlation between BMP signaling expression levels in ALK3QD
clones and ability to form tumours on the chick CAM
For each ALK3QD clone, 1 x 106 cells were inoculated onto the surface of the

chick CAM, and were then incubated for one week at which time tumour formation was
assessed. In addition to the ALK3QD clones, parental cells were also inoculated onto the
chick CAM. Upon brightfield and fluorescence imaging of tumours formed on the CAM
from these clones, MOSERM ALK3QD clone 1 (+) and clone 2 (+) are visibly smaller
than tumours formed by the MOSERM parental cell line (Figure 3.7A). Similarly, 4306
ALK3QD clone 2 (+) derived tumours are visibly smaller than those formed by parental
4306 cells. Conversely, tumours that were formed by 4306 ALK3QD clone 1 (-) cells
were visibly larger than those formed by parental 4306 cells. Although MASC2, MASC2
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Figure 3.7

Differences in size of tumours formed on the chick CAM among

ALK3QD stably-transfected mouse EOC cell line clones.
Approximately 1 x 106 cells were seeded onto the surface o f the CAM for each ALK3QD
clone and their respective parental cell lines. (A) Brightfield and fluorescence images
were taken o f the cell xenograft locations at 20X magnification 7 days after the initial
seeding. MOSERM (B) and 4306 (C) tumours were then excised from the surface o f the
chick CAM, fixed in formalin overnight, and weighed. Error bars represent the standard
error o f the mean o f tumour weights from at least 5 excised tumours per group. Different
letters represent statistically significant differences among groups (p < 0.01). Scale bars:
2 mm.
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ALK3QD clone 1 (-) and clone 2 (-) cells were also inoculated onto the surface of the
CAM, they did not form visible tumours (data not shown). These qualitative observations
of differences in tumour size were subsequently quantified by measuring tumour weight,
which was accomplished by excising tumours after imaging, placing in formalin
overnight and then weighing them. Tumours that were formed from MOSERM parental
cells weighed approximately 8.3 ± 0.8mg, which had a significantly greater mass than
both the MOSERM ALK3QD clone 1 (+) (p < 0.001) and clone 2 (+) (p < 0.01) chick
CAM tumours (Figure 3.7B). The tumours formed by these clones weighed
approximately 5.2 ± 0.3mg and 4.4 ± 0.7mg respectively, and their masses were not
significantly different from one another. With respect to 4306 ALK3QD clones, the
average weight of 4306 ALK3QD clone 2 (+) tumours was 1.7 ± 0.4mg compared to
4306 parental cell derived tumours that were approximately 3.3 ± 0.4mg (Figure 3.7C).
Although this indicates a trend towards decreased tumour mass in 4306 ALK3QD clone 2
(+) relative to 4306 parental cells, this difference is not statistically significant.
Conversely, 4306 ALK3QD clone 1 (-) cells form tumours that weigh approximately 10.7
± 0.7mg, and have a significantly greater mass than 4306 parental cells (p < 0.001).

3.8

Changes in BMP signaling due to ALK3QD expression do not affect cell
proliferation in vitro
In order to determine which mechanism(s) might be contributing to the

differences that are seen between ALK3QD clones and parental cells with respect to their
abilities to form tumours on the chick CAM, we decided to first investigate cell
proliferation as a potential mechanism. This was accomplished by completing
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alamarBlue® assays in vitro in full serum over a period of five days, and proliferation was
quantified fluorometrically at days 0, 1,2, 3, and 5 for all mouse EOC cell lines and their
respective ALK3QD clones. By day 5, the fluorimetric counts for MOSERM, MOSERM
ALK3QD clone 1 (+), and MOSERM ALK3QD clone 2 (+) were not significantly
different from one another (Figure 3.8A). As well, there were no significant differences
in proliferation between MASC2 parental cells and MASC2 ALK3QD clones (Figure
3.8B). Finally, neither 4306 ALK3QD clone displayed statistically significant differences
in proliferation relative to 4306 parental cells (Figure 3.8C).

3.9

Inverse correlation between level of BMP signaling in mouse EOC ALK3QD
clones and degree of blood vessel sprouting on the chick CAM
Since altered BMP signaling does not correlate with in vitro cell proliferation in

mouse EOC cell lines, I next sought to determine whether angiogenesis might be a
potential mechanism contributing to the differences that are seen among ALK3QD clones
and parental cells with respect to their abilities to form tumours on the chick CAM.
Angiogenesis was assessed on the chick CAM using the collagen onplant assay as
previously described, and angiogenesis was quantified by expressing the number of grids
that are positive for blood vessel sprouting as a percentage of total grids in each mesh.
Collagen onplants containing MOSERM cells contributed to new blood vessel sprouting
in approximately 20.1 ± 2.0% of grid boxes (Figure 3.9A). This induction of
angiogenesis was significantly greater than the PBS control group (11.4 ± 1.3% of grid
boxes; p < 0.01), the MOSERM ALK3QD clone 1 (+) group (6.0 ± 1.5% of grid boxes; p
< 0.001), and the MOSERM ALK3QD clone 2 (+) group (11.6 ± 2.4% o f grid boxes; p <
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Figure 3.8

No effect of ALK3QD expression of mouse EOC cell line proliferation

in vitro.

In order to assess cell proliferation, alamarBlue® assays were performed. 500 cells were
seeded into 96 well plates for (A) MOSERM parental cells, MOSERM ALK3QD clone 1
(+) and clone 2 (+), (B) MASC2 parental cells, MASC2 ALK3QD clone 1 (-) and clone 2
(-), (C) 4306 parental cells, 4306 ALK3QD clone 1 (-) and clone 2 (+). Fluorescence
units were then measured 12 hours after the initial seeding time in order to ensure equal
seeding densities (day 0), and fluorescence units were then subsequently measured again
at multiple time points (day 1, day 3, day 5). Each data point represents the average of at
least 3 wells.
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Figure 3,9

ALK3QD expression in mouse EOC cell lines influences the

angiogenic potential of cells on the chick CAM in vivo.
1 x 105 cells for each o f the MOSERM, MASC2, and 4306 cell lines as well as for their
respective ALK3QD clones were embedded in collagen. The collagen with mouse EOC
cells was then inserted between 2 mesh grids, and placed on the surface of the chick
CAM for 3 days, at which time angiogenesis was quantified. Angiogenesis was
quantified by calculating the percentage of grid boxes within each mesh that were
positive for blood vessel sprouting. Note that if a grid is determined to be positive for
blood vessel sprouting, the grid count will only be given a score of one regardless of how
many sprouts are within that grid box. The percentage of grids that are positive for blood
vessel sprouting for (A) MOSERM, MOSERM ALK3QD clone 1 (+) and clone 2 (+),
(B) MASC2, MASC2 ALK3QD clone 1 (-) and 2 (-), (C) 4306, 4306 ALK3QD clone 1
(-) and clone 2 (+) are shown. Error bars represent standard error o f the mean for the
average percentage of positive grids based on at least 7 mesh grids per group. Different
letters represent statistically significant differences between groups (p < 0.05).
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0.05). However, there are no statistically significant differences in angiogenic sprouting
between the PBS, MOSERM ALK3QD clone 1 (+), or MOSERM ALK3QD clone 2 (+)
treatment groups. Collagen onplants containing MASC2 parental cells contributed to new
blood vessel sprouting on the chick CAM in 12.0 ± 2.7% of the grid boxes (Figure 3.9B).
However, this degree of sprouting is not significantly different from the PBS group (9.5 ±
0.7% grid boxes), MASC2 ALK3QD clone 1 (-) group (14.4 ± 0.7% grid boxes), or the
MASC2 ALK3QD clone 2 (-) treatment group (15.4 ± 0.9% grid boxes). Conversely, the
degree o f angiogenic sprouting in the MASC2 ALK3QD clone 1 (-) and clone 2 (-)
treatment groups is significantly greater than in the PBS control group (p < 0.05). Finally,
13.6 ± 1.0% o f grid boxes exhibited new blood vessel sprouting in collagen onplants
containing 4306 parental cells (Figure 3.9C), which is significantly greater than blood
vessel formation levels in the PBS control group (10.3 ± 0.7% grid boxes; p < 0.05).
Although there is a trend towards increased blood vessel sprouting in the 4306 ALK3QD
clone 1 (-) group (16.8 ± 1.1% grid boxes), it is not significantly different from the 4306
parental group. Conversely, 4306 ALK3QD clone 2 (+) collagen onplants exhibit new
blood vessel sprouting in 9.7 ± 0.7 % o f grid boxes, which is significantly decreased
compared to both the 4306 parental (p < 0.05) and 4306 ALK3QD clone 1 (-) groups (p <
0. 01) .

3.10

Treatment of mouse EOC cells with exogenous BMP4, Noggin, or BMP type
1 receptor inhibitor LDN-193189
In order to support my ALK3QD findings, we investigated whether short-term

changes in BMP pathway signaling expression would have functional consequences on

cell proliferation and angiogenesis. Therefore, the three mouse EOC cell lines were
treated with exogenous BMP4, Noggin (extracellular antagonist to inhibit BMP ligand
binding) (Groppe, Greenwald et al. 2002) or LDN-193189 (BMP type 1 receptor
inhibitor) (Yu, Deng et al. 2008). We first wanted to confirm that exogenous treatment
with BMP4, Noggin, or LDN-193189 would affect the BMP signaling pathway, and to
determine the duration o f these effects. Therefore, cells were treated at the onset o f the
experiment, and protein was isolated from cells at multiple time points over three days
(30 min, 4 hours, 24 hours, 48 hours, and 72 hours). Upon treatment with lOng/mL
BMP4, protein levels o f phospho-Smad 1/5/8 were increased in all three mouse EOC cell
lines within 30 minutes (Figure 3.10A). The increase in phospho-Smadl/5/8 levels in
MOSERM cells remained elevated up to the last time point at 72 hours, whereas the
effect was diminished in MASC2 and 4306 cells by 24 hours. To a lesser extent, Idl
protein expression was upregulated in MOSERM cells after 4 hours, and remained
upregulated at 72 hours. Conversely, there were no consistent changes in Idl expression
in the other cell lines.
After treatment with either 50ng/mL Noggin or 40nM LDN-193189, phosphoSmad 1/5/8 protein levels decreased in all three cell lines within 30 minutes (Figures
3.10B and 3.10C). While these effects were sustained over the 72 hours of the experiment
in MOSERM cells, phospho-Smad 1/5/8 expression began to noticeably increase back
towards baseline levels after approximately 24-48 hours in the MASC2 and 4306 cells
that were treated with Noggin and LDN-193189. Treatment with either o f these BMP
signaling inhibitors did not have an effect on Idl protein expression in MOSERM or
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Figure 3.10

Changes in BMP signaling as a result of treatment of mouse EOC cell

lines with BMP4, Noggin, or LDN-193189.
Changes in downstream BMP signaling at multiple time points (30min, 4h, 24h, 48h,
72h) after (A) lOng/mL BMP4 treatment, (B) 50ng/mL Noggin treatment, or (C) 40nM
LDN-193189 treatment were assessed using anti-phospho-smad 1/5/8 and anti-IDl.
Western blotting was performed using 50pg o f total cellular protein, and equal loading
was assessed with anti-Smadl and anti-actin. BMP signaling was considered to be
upregulated or downregulated based on a change in phospho-Smad 1/5/8 protein
expression. BMP4 treatment resulted in an upregulation of BMP signaling, while
treatment with Noggin or LDN-193189 downregulated BMP signaling.
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MASC2 compared to untreated cells. Idl expression did decrease in 4306 cells by 30
minutes, although it began to increase back to levels in untreated cells by 24 hours.

3.11

Changes in BMP signaling due to BMP4, Noggin, or LDN-193189 treatment
do not affect cell proliferation or cell survival in vitro
In order to determine the functional consequences of the changes that were seen

in protein expression levels in the BMP signaling pathway as a result of short-term
BMP4, Noggin, or LDN-193189 treatment, cell proliferation and survival were initially
assessed. For each cell line, BMP4 and Noggin treated cell proliferation was compared to
parental cell line proliferation in growth media. Cell proliferation due to LDN-193189
treatment was compared to cells that were grown in media with 3 DMSO: 1 chloroform,
which is the solvent for LDN-193189. In vitro alamarBlue® assays were completed over a
five day period, and fluorometric counts o f wells were taken each day. For the
MOSERM, MASC2, and 4306 cell lines, the average fluorometric counts for parental
cells, BMP4 treatment, or Noggin treatment were not significantly different from one
another at day 5 ( Figure 3.11). Similarly, there were no significant differences in the day
5 fluorometric counts for any o f the three cell lines between 3 DMSO: 1 chloroform and
LDN-193189 treatments.
The ability o f each of the three mouse EOC cell lines to survive in serum-free
conditions in vitro after treatment was also evaluated. As with the in vitro cell
proliferation assay, cell survival was assessed every 24 hours over 5 days by alamarBlue®
fluorometric counts. However, cells were grown in serum-free media instead of media
with 5% FBS. Similar to our findings with respect to cell proliferation, changes in the
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Figure 3.11

No effect of BMP4, Noggin, or LDN-193189 treatment of mouse EOC

cell lines on cell proliferation in vitro.
In vitro alamarBlue® assays were performed to assess cell proliferation, which was
compared between parental cells, BMP4-treated cells, Noggin-treated cells, LDN193189treated cells, and cells treated with the solvent for LDN193189 (3 DMSO:l chloroform).
500 cells in media with 5% FBS were seeded into 96 well plates for (A) MOSERM cells
and respective treatments, (B) MASC2 cells and respective treatments, and (C) 4306 cells
and respective treatments. Fluorescence units were then measured 12 hours after the
initial seeding in order to ensure equal seeding densities (day 0), and fluorescence units
were then subsequently measured again at multiple time points (day 1, day 2, day 3, day
4, day 5). Each data point represents the average of at least 3 wells.
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ability of cells to survive were not statistically significant among any of the three cell
lines for any treatment (Figure 3.12). Interestingly, the fluorescence unit counts for the
4306 cell line and its respective treatment groups plateau over the five day experimental
period, whereas the fluorometric counts for the MOSERM and MASC2 cell lines steadily
decrease between days 1 and 5.

3.12

Treatment of mouse EOC cell lines with exogenous BMP4 ligand decreases
the ability of cells to induce angiogenesis in vitro
Since short-term treatment with BMP4, Noggin, or LDN-193189 did not affect

cell proliferation or survival, I sought to determine whether these treatments affected the
ability of the mouse EOC cell lines to induce angiogenesis in vitro. This is because there
was an inverse correlation between BMP signaling levels in ALK3QD clones and the
angiogenic potential of these cells. Therefore, parental cells were treated overnight for 12
hours with media containing lOng/mL BMP4 or 50ng/mL Noggin. After this period of
time, treated cells were co-cultured with HUVECs in low serum-containing media (1%
FBS) on a layer o f Matrigel in the wells o f 96-well plates. After 6 hours o f incubation,
multiple images were taken o f each well at 100X magnification. Treatment with BMP4
significantly decreased HUVEC branching from an average of 16.5 ± 0.5 branches per
field of view for untreated MOSERM cells to 14.3 ± 0.5 branches per field of view in
BMP4-treated MOSERM cells (Figure 3.13A; p = 0.005). Similarly, HUVEC branching
significantly decreased from 8.2 ± 0.9 to 5.4 ± 0.6 branches per field of view between
untreated MASC2 cells and BMP4-treated cells (Figure 3.13B; p = 0.04). As well,
HUVEC branching significantly decreased from HUVECs co-cultured with untreated
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Figure 3.12

No effect of BMP4, Noggin, or LDN-193189 treatment of mouse EOC

cell lines on cell survival in vitro.
In vitro alamarBlue® assays were performed to assess cell survival, which was compared
between parental cells, BMP4-treated cells, Noggin-treated cells, LDN193189-treated
cells, and cells treated with the solvent for LDN 193189 (3 DMSO:l chloroform). 5000
MOSERM cells, 5000 MASC2 cells, or 10,000 4306 cells in serum-free media were
seeded into 96 well plates for (A) MOSERM cells and respective treatments, (B) MASC2
cells and respective treatments, and (C) 4306 cells and respective treatments.
Fluorescence units were then measured 12 hours after the initial seeding in order to
ensure equal seeding densities (day 0), and fluorescence units were then subsequently
measured again at multiple time points (day 1, day 2, day 3, day 4, day 5). Each data
point represents the average of at least 3 wells.
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Figure 3.13

Short-term treatment of mouse EOC cell lines with BMP4 or Noggin

affects ability of cells to induce angiogenesis in vitro.
1 x 104 HUVECs were plated onto Matrigel and co-incubated with 5000 MOSERM cells,
MASC2 cells, or 4306 cells in low serum-containing media (1% FBS) in 96 well plates.
After 6 hours, angiogenesis was quantified by counting the number o f branches formed
by HUVECs per field of view in each well at 100X magnification. Branch counts for (A)
MOSERM cells and respective treatments, (B) MASC2 cells and respective treatments,
(C) 4306 cells and respective treatments are shown. Untreated cell branch counts per field
o f view are represented by black bars, while branch counts for BMP4 or Noggin-treated
cells are represented by grey bars. Error bars represent standard error o f the mean for the
average number o f branches based on at least 4 wells per group. Asterisks indicate
statistically significant differences within each pair of columns (p < 0.05). Pairwise
comparisons were made between each treatment and its control.
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4306 cells at 10.7 ± 0.2 branches per field o f view to 8.9 ± 0.7 branches per field of view
in co-cultures with BMP4-treated 4306 cells (Figure 3.13C;p - 0.04). Upon treatment of
cells with Noggin for 12 hours, branching was increased relative to untreated cells by 1.2
±1.1 branches per field o f view for MOSERM Noggin-treated cells, 3.1 ± 1.0 branch
points per field o f view for MASC2 Noggin-treated cells, and by 2.3 ± 0.6 branch points
per field o f view for 4306 Noggin-treated cells. However, this trend towards increased
HUVEC branching in Noggin-treated cells is not statistically significant for any cell line.
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CHAPTER FOUR

DISCUSSION

4.1

Summary
Ovarian cancer continues to be a poorly understood disease with respect to the

signs and symptoms relating to the early stages o f EOC, as well as with respect to the
molecular mechanisms that contribute to its progression from a localized tumour that is
confined to the ovaries to one that can metastasize to distant sites within the peritoneal
cavity (Goff, Mandel et al. 2007). The poor understanding of this disease is highlighted
by it having the highest mortality rate o f any gynaecological cancer in the developed
world, and decreases in this mortality rate have been relatively minimal when compared
to other cancers that have seen more successful improvements in mortality rates over the
past 15 years such as breast cancer (Canada 2010). Therefore, several key approaches
must be employed in order to significantly reduce the high mortality rates that are
associated with EOC in the future. One of these approaches is to improve current models
o f EOC in vitro and in vivo, or to develop novel model systems that can be efficiently
used to study various aspects of EOC progression. Another key approach will be to
further our understanding o f the role(s) o f molecular signaling pathways that have been
implicated in other forms o f cancer and specifically EOC, such as the BMP signaling
pathway (Shepherd and Nachtigal 2003; Moll, Millet et al. 2006; Theriault, Shepherd et
al. 2007; Shepherd, Theriault et al. 2008; Ma, Ma et al. 2010; Pils, Wittinger et al. 2010;
Shepherd, Mujoomdar et al. 2010; McLean, Gong et al. 2011).
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My studies have shown that the relative abilities of the MOSERM, MASC2, and
4306 mouse EOC cell lines to form tumours on the chick CAM correlates with their
differential abilities to enhance angiogenesis in vitro. Importantly, I was also able to
detect these differences in angiogenic potential in vivo using the chick CAM collagen gel
angiogenesis onplant assay. I have also shown that in addition to normal mouse OSE
cells, the MOSERM, MASC2, and 4306 cell lines all express measurable, but distinct
levels o f BMP4 and its required intracellular signaling components. ALK3QD clones
created from each cell line with increased BMP signaling relative to parental cells formed
significantly smaller tumours on the chick CAM, while clones with decreased BMP
signaling formed larger tumours on the chick CAM relative to parental cells.
Additionally, increased BMP signaling in mouse EOC cell lines leads to decreased
HUVEC branching in vitro, and decreased blood vessel formation in vivo using the chick
CAM angiogenesis onplant assay. Conversely, cells with decreased BMP signaling
exhibited increased levels of angiogenesis both in vitro and in vivo.
With respect to EOC mouse cells, there is only one mouse EOC cell line that has
been well characterized in multiple studies, which is the ID8 mouse EOC cell line
(Pengetnze, Steed et al. 2003). ID8 cells were created from normal mouse OSE cells that
spontaneously transformed after repeated passaging in vitro. This cell line has multiple
benefits because it exhibits an upregulation of Src tyrosine kinase, FAK, and PI3K/AKT
signaling activation that in combination increase the rate o f growth o f ID8 cells, and
decrease apoptosis. These signaling pathways have also been shown to be dysregulated in
a large percentage o f ovarian cancers (Judson, He et al. 1999; Wiener, Windham et al.
2003; Huang, Zhang et al. 2011; Tanaka, Terai et al. 2011). Additionally, ID8 cells are
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able to form tumours and ascites when injected into mice with intact immune systems
(Roby, Taylor et al. 2000). However, other than this cell line, there are only a couple
other mouse EOC cell lines that have been used and partially characterized in the
literature (Szotek, Pieretti-Vanmarcke et al. 2006; Goodell, Belisle et al. 2009), although
to a lesser extent than ID8 cells. Therefore, the development and characterization of other
mouse EOC cell lines will be very beneficial and will contribute to an improved
understanding o f EOC and its progression. As a result, our lab obtained three mouse
ovarian cancer cell lines that I partially characterized both in vitro and in vivo. The first
cell line is the 4306 cell line that overexpresses mutant Kras ' 120 in addition to having an
inactivated Pten tumour suppressor gene (Dinulescu, Ince et al. 2005). Secondly, the
MOSERM line ectopically expresses the Ras and Myc oncogenes in addition to a
temperature sensitive mutant of SV40 large T antigen (Yao, Li et al. 2006). Thirdly, the
MASC2 cell line expresses SV40 large T antigen (Laviolette, Garson et al. 2010).
Although the 4306 cell line has been shown to possess an intact Mullerian Inhibiting
Substance (MIS) signal transduction pathway (Szotek, Pieretti-Vanmarcke et al. 2006),
these three mouse EOC cell lines have otherwise been poorly characterized in the
literature. Therefore, our characterization of the MOSERM, MASC2, and 4306 cell lines
with respect to their in vivo tumour formation abilities on the chick CAM, in vitro
proliferation, in vitro angiogenesis, and angiogenesis on the chick CAM will support the
use o f these cell lines as additional tools to gain a better understanding of EOC.
Also contributing to our lack of understanding o f EOC is a limited number of
effective in vivo animal model systems that can recapitulate multiple aspects of EOC
tumour progression (Pengetnze, Steed et al. 2003). The chick CAM is a useful animal

104
model system that has been used to study many types o f cancer including colon (Kim,
Hur et al. 2011), melanoma (Liang, Butterfield et al. 2011), neuroblastoma (Azar, Azar et
al. 2011), oral squamous cell carcinoma (Hseu, Wu et al. 2011), pancreatic cancer
(Laklai, Laval et al. 2009). In addition, this system can been used to investigate several
aspects o f tumourigenesis such as primary tumour growth (Gao, Cao et al. 2004; Liang,
Butterfield et al. 2011), metastasis (Subauste, Kupriyanova et al. 2009), and angiogenesis
(Azar, Azar et al. 2011; Chim, Qin et al. 2011; Liang, Butterfield et al. 2011). With
respect to ovarian cancer, the chick CAM can be used to simulate the physiological
microenvironment that metastatic EOC cells would be subjected to in the peritoneal
cavity when encountering mesothelial surfaces o f abdominal organs and a vascularized
substratum upon which cells will form secondary metastases (Schmitt and Matei 2011).
The chick CAM has previously been applied to EOC to study the effects of two
naturally occurring flavonoids, Kaempferol and Apigenin, on tumour growth and
angiogenesis. Both of these flavonoids were shown to decrease angiogenesis in chick
CAM assays with human ovarian cancer OVCAR3 cells, while Kaempferol was also
shown to limit OVCAR3 tumour growth on the chick CAM (Fang, Zhou et al. 2007; Luo,
Rankin et al. 2009). Additionally, malignant ascites fluid (MAF) has been shown to
decrease surface capillary formation when it was applied directly to the surface o f the
chick CAM (Richardson, Gunawan et al. 2002). We have added evidence in addition to
these studies that further supports the use o f the chick CAM as an effective model system
that can be used study tumour formation and angiogenesis in EOC progression.
Importantly, other than our collaborations with Dr. John Lewis and his lab, only a few
other labs in the world have used the collagen onplant assay on the chick CAM to
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quantify angiogenesis (Nguyen, Shing et al. 1994; Seandel, Noack-Kunnmann et al.
2001; Zijlstra, Seandel et al. 2006). Although other chick CAM angiogenesis assays can
be useful, they are only qualitative and it can be difficult to distinguish new blood vessel
formation from preexisting blood vessels (Staton, Reed et al. 2009). Therefore, our lab is
using the novel chick CAM onplant assay that has the ability to detect more subtle
changes in angiogenesis by quantifying new blood vessel formation, which may not have
been detectable in our studies if traditional chick CAM angiogenesis assays that are more
qualitative had been used (Nguyen, Shing et al. 1994).
Angiogenesis is one the essential hallmarks of cancer because tumours require
access to a blood supply in order to receive oxygen and nutrients, and to be able to
excrete waste products such as carbon dioxide (Hanahan and Folkman 1996). In fact,
without the ability to induce a certain level of angiogenesis, tumours cannot grow and
survive beyond a size of 1-2 mm in diameter (Bergers and Benjamin 2003). The
importance o f angiogenesis in the progression o f cancer is reflected by the large number
of current trials involving anti-angiogenic compounds that are being tested in patients
with metastatic ovarian cancer. For example, there are over 25 ongoing phase I, phase II,
or phase III clinical trials that involve one or more of the anti-angiogenic agents
Bevacizumab, Dasatinib, Imatinib, or Sorafenib as monotherapies or in combination with
other drugs (Schmitt and Matei 2011). Due to the importance o f angiogenesis in cancer
metastasis, it is essential to gain a thorough understanding of the signaling pathways that
play an important role in this process. Therefore, I have focused my studies on the role of
the BMP signaling pathway on tumour angiogenesis. BMP signaling has been shown to
have an important pro-angiogenic role in many cancers such as hepatocellular cancer
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(Maegdefrau, Amann et al. 2009) and melanoma (Rothhammer, Bataille et al. 2007), but
has also been implicated in having an anti-angiogenic role in others such as lung cancer
(Buckley, Shi et al. 2004). However, the role o f BMP signaling in the process of
angiogenesis has never been previously studied in EOC. Based on my findings, I propose
that one o f the important mechanism(s) by which increased BMP signaling is able to limit
the ability of mouse EOC cells to form tumours on the CAM is by decreasing the
angiogenic potential of these cells. Interestingly, my characterization o f TGFp/BMP gene
expression in the three mouse EOC cell lines also supports these findings. For example,
MASC2 cells exhibit significantly higher expression levels of BMP4, as well as Idl and
ld2. These cells are also unable to form visible tumours on the chick CAM, and do not
significantly induce angiogenesis relative to growth media and PBS controls for in -vitro
and in vivo angiogenesis assays, respectively. This is compared to MOSERM and 4306
cells that exhibit lower expression levels of BMP signaling genes, are able to form
tumours on the chick CAM, and significantly enhance angiogenesis relative to controls
both in vitro and in vivo. Therefore, I propose that MASC2 cells are unable to form
tumours on the chick CAM due to the fact that they have a limited ability relative to other
mouse EOC cell lines to enhance angiogenesis, and this decreased ability to enhance
angiogenesis is partially due to increased BMP signaling.
Although angiogenesis is essential for tumours to metastasize, there are other
mechanisms that are also important in cancer progression. Several o f these mechanisms
have been studied with respect to the BMP4 signaling pathway and its role in EOC
progression in several studies. For example, increased BMP4 signaling in vitro has been
shown to lead to morphological changes in cells that are characteristic of an EMT
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transition (Shepherd and Nachtigal 2003; Theriault, Shepherd et al. 2007), a loss of cell
adhesion (Shepherd, Mujoomdar et al. 2010), increased motility, and increased invasive
potential (Theriault, Shepherd et al. 2007). Similarly, studies that involve decreasing the
activity level o f the BMP signaling pathway through the use of Noggin and Chordin in
EOC cells decreased their migration and invasive potential, as well as increased cell
adhesion (Moll, Millet et al. 2006; Theriault, Shepherd et al. 2007). However, a recent
conflicting study involving constitutively active BMP signaling with ALK3QD has
correlated increased BMP signaling with a decreased ability o f EOC cells to form
intraperitoneal tumour implantations in addition to decreased ascites formation when
injected into mice (Shepherd, Mujoomdar et al. 2010). My findings show that mouse
EOC cells with increased levels of BMP signaling form significantly smaller tumours on
the chick CAM, which acts to simulate the physiological microenvironment that EOC
cells would encounter when metastasizing to the substratum of the peritoneal cavity , and
this decreased ability to form secondary tumours is due to a decreased ability to enhance
angiogenesis. Therefore, my data supports the previously conflicting study that implicates
BMP signaling as an anti-tumourigenic pathway in the later stages of EOC progression.
In order to connect these two disparate groups o f data, I propose that BMP signaling has
unique roles at different stages o f ovarian cancer progression. During the early stages of
EOC tumour progression, upregulated BMP signaling is advantageous so that EOC cells
can lose their adhesion capabilities, and as a result are able to shed from the primary
tumour into the peritoneal cavity. However, in later stages of ovarian cancer progression,
downregulated BMP signaling is required to promote spheroid formation and the
establishment of secondary métastasés at distant sites within the peritoneal cavity. The
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ability to recruit vasculature is a key component for tumours to be able to establish these
secondary métastasés. Decreased BMP signaling will therefore improve the ability of
tumours to recruit vasculature at these secondary sites, and as a result will be better able
to grow and survive upon reattachment.
Due to the complicated nature of the BMP signaling pathway both with respect to
its activation and regulation, as well as its multiple roles in various stages of EOC
progression, further research will be required in order to gain a more thorough
understanding o f this pathway in ovarian cancer despite the recent and ongoing
advancements in our lab. However, this pathway has important potential future
implications for prognostics. For example, elevated BMP4 and potentially BMP2 levels
with ovarian cancer could be considered in order to assist with prognoses for patients.
This is because decreased BMP levels in patients would be considered to be a negative
prognostic factor due to the fact it would correlate with an increased ability o f the EOC
tumour to further metastasize, and as a result correlate with lower survival outcomes.
Additionally, targeting the BMP pathway has potential therapeutic value. For example, in
patients with more advanced stages o f EOC in which the tumour has already begun to
metastasize, therapeutics could possibly be used to increase levels of BMP signaling in
EOC cells. This could decrease the ability of additional EOC cells from forming
secondary nodules, and could also decrease the survival ability of already metastasized
tumours by limiting their abilities to recruit a sufficient blood supply.
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4.2

Future directions
BMP signaling as an anti-angiogenic pathway in cancer is a fairly novel concept

that has only come to light in the past decade (Buckley, Shi et al. 2004; Stabile, Mitola et
al. 2007). O f these studies, there is only one of which we are aware that suggests a
potential downstream target o f increased BMP signaling that contributes to decreased
angiogenesis in cancer. This study by Stabile et al. suggests that in lung cancer, increased
BMP4 signaling leads to decreased VEGF protein expression (Stabile, Mitola et al.
2007). Our lab plans to contribute to BMP signaling research in cancer by investigating
potential downstream targets o f increased BMP signaling that lead to a decreased ability
of mouse ovarian cancer cells to enhance angiogenesis. This will be accomplished by
comparing the mRNA or protein expression levels of well known pro-angiogenic factors
such as VEGF as well as angiogenesis inhibitors such as TSP-1 in our ALK3QDtransfected clones, BMP4-treated cells, Noggin-treated cells, or LDN-193189-treated
cells. Expression levels will then be compared to the untreated parental mouse EOC cell
lines. An alternative approach will be to use RNA or protein-based array screens that are
specifically designed to evaluate a large number of angiogenic growth factors and related
proteins. We also plan to conduct future experiments in order to provide additional
evidence that angiogenesis is responsible for the differential abilities of the three mouse
EOC cell lines to form tumours on the chick CAM. Based on my current data, I
hypothesize that MASC2 cells would be able to form tumours on the chick CAM if the
angiogenic potential o f these cells was significantly increased. Therefore, MASC2 cells
will be transfected in order to overexpress a major pro-angiogenic factor such as VEGF,
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after which time these transfected cells will be inoculated onto the surface o f the chick
CAM to assess tumour growth.
My studies have further supported the use of the chick CAM as an effective
model system that can be used to study EOC. Although there has been one study that has
investigated the effects o f whole MAF from patients with ovarian cancer on angiogenesis
by inoculating this fluid onto the surface of the CAM (Richardson, Gunawan et al. 2002),
there have been no studies of which we are aware that have used the chick CAM to study
primary human EOC cells specifically. Therefore, my findings relating to the role of
BMP signaling in mouse EOC cells on the chick CAM now provides an initial starting
point from which our lab will be able to assess the effect of altered BMP signaling on
tumour growth and angiogenesis in primary human EOC cells using this model system.
These primary human EOC cells will be directly isolated from patient ascites fluid by
using a protocol that was previously developed by Dr. Trevor Shepherd (Shepherd,
Theriault et al. 2006). Additionally, the ease o f use and large-scale applicability of the
chick CAM model system provides unique opportunities in the future to rapidly test
novel therapeutic compounds, specifically compounds targeting BMP signaling pathway
in EOC that can be directly tested in this model system. For example, anti-angiogenic
agents that would act by enhancing BMP signaling and therefore decrease the angiogenic
potential of metastatic EOC tumours could be applied to the chick CAM, which could
then lead to mouse and human trials, and eventually to improved therapeutic outcomes
for patients.
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Principal investigator: Dr. John Lewis
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metastasis in cancer
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